```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAVXR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  DEC 01  ChemPort single article sales feature unavailable
 NEWS  3  APR 03  CAS coverage of exemplified prophetic substances
                  enhanced
 NEWS  4  APR 07  STN is raising the limits on saved answers
 NEWS  5  APR 24  CA/CAplus now has more comprehensive patent assignee
                  information
 NEWS  6  APR 26  USPATFULL and USPAT2 enhanced with patent
                  assignment/reassignment information
 NEWS  7  APR 28  CAS patent authority coverage expanded
 NEWS  8  APR 28  ENCOMPLIT/ENCOMPLIT2 search fields enhanced
 NEWS  9  APR 28  Limits doubled for structure searching in CAS
                  REGISTRY
 NEWS 10  MAY 08  STN Express, Version 8.4, now available
 NEWS 11  MAY 11  STN on the Web enhanced
 NEWS 12  MAY 11  BEILSTEIN substance information now available on
                  STN Easy
 NEWS 13  MAY 14  DGENE, PCTGEN and USGENE enhanced with increased
                  limits for exact sequence match searches and
                  introduction of free HIT display format
 NEWS 14  MAY 15  INPADOCDB and INPAFAMDB enhanced with Chinese legal
                  status data
 NEWS 15  MAY 28  CAS databases on STN enhanced with NANO super role in
                  records back to 1992
 NEWS 16  JUN 01  CAS REGISTRY Source of Registration (SR) searching
                  enhanced on STN

 NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
              AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:27:52 ON 12 JUN 2009
```

```
=> file registry
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.22       0.22

FILE 'REGISTRY' ENTERED AT 16:28:36 ON 12 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   10 JUN 2009  HIGHEST RN 1155458-91-5
DICTIONARY FILE UPDATES:  10 JUN 2009  HIGHEST RN 1155458-91-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> exit
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         3.36       3.58

STN INTERNATIONAL LOGOFF AT 16:32:34 ON 12 JUN 2009



Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAVXR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  DEC 01  ChemPort single article sales feature unavailable
 NEWS  3  APR 03  CAS coverage of exemplified prophetic substances
                  enhanced
 NEWS  4  APR 07  STN is raising the limits on saved answers
```

```
 NEWS  5  APR 24  CA/CAplus now has more comprehensive patent assignee
                  information
 NEWS  6  APR 26  USPATFULL and USPAT2 enhanced with patent
                  assignment/reassignment information
 NEWS  7  APR 28  CAS patent authority coverage expanded
 NEWS  8  APR 28  ENCOMPLIT/ENCOMPLIT2 search fields enhanced
 NEWS  9  APR 28  Limits doubled for structure searching in CAS
                  REGISTRY
 NEWS 10  MAY 08  STN Express, Version 8.4, now available
 NEWS 11  MAY 11  STN on the Web enhanced
 NEWS 12  MAY 11  BEILSTEIN substance information now available on
                  STN Easy
 NEWS 13  MAY 14  DGENE, PCTGEN and USGENE enhanced with increased
                  limits for exact sequence match searches and
                  introduction of free HIT display format
 NEWS 14  MAY 15  INPADOCDB and INPAFAMDB enhanced with Chinese legal
                  status data
 NEWS 15  MAY 28  CAS databases on STN enhanced with NANO super role in
                  records back to 1992
 NEWS 16  JUN 01  CAS REGISTRY Source of Registration (SR) searching
                  enhanced on STN

 NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
              AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:46:52 ON 15 JUN 2009

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.44       0.44

FILE 'REGISTRY' ENTERED AT 09:48:09 ON 15 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)
```

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2009 HIGHEST RN 1157585-76-6
DICTIONARY FILE UPDATES: 14 JUN 2009 HIGHEST RN 1157585-76-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.96	1.40

FILE 'STNGUIDE' ENTERED AT 09:49:34 ON 15 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jun 12, 2009 (20090612/UP).

=> file zcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.07	1.47

FILE 'ZCAPLUS' ENTERED AT 09:49:47 ON 15 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 15 Jun 2009 VOL 150 ISS 25
FILE LAST UPDATED: 14 Jun 2009 (20090614/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> e US2006-584280/apps
E1            2     US2006-584277/AP
E2            1     US2006-584277/PRN
E3            1 --> US2006-584280/AP
E4            0     US2006-584280/PRN
E5            1     US2006-584282/AP
E6            1     US2006-584283/AP
E7            1     US2006-584284/AP
E8            1     US2006-584285/AP
E9            1     US2006-584287/AP
E10           1     US2006-584288/AP
E11           1     US2006-584290/AP
E12           1     US2006-584290/PRN

=> s US2006-584280/apps
              1 US2006-584280/AP
              0 US2006-584280/PRN
L1            1 US2006-584280/APPS
                  (US2006-584280/AP,PRN)

=> sel rn
E1 THROUGH E70 ASSIGNED

=> file registry
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   5.90       7.37

FILE 'REGISTRY' ENTERED AT 09:51:11 ON 15 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   14 JUN 2009  HIGHEST RN 1157585-76-6
DICTIONARY FILE UPDATES:  14 JUN 2009  HIGHEST RN 1157585-76-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s e1-e70
              1 100-39-0/BI
                  (100-39-0/RN)
```

1 103-80-0/BI
(103-80-0/RN)
1 1073-69-4/BI
(1073-69-4/RN)
1 108-69-0/BI
(108-69-0/RN)
1 110937-65-0/BI
(110937-65-0/RN)
1 16563-14-7/BI
(16563-14-7/RN)
1 175463-32-8/BI
(175463-32-8/RN)
1 1939-99-7/BI
(1939-99-7/RN)
1 214542-52-6/BI
(214542-52-6/RN)
1 214542-59-3/BI
(214542-59-3/RN)
1 285984-25-0/BI
(285984-25-0/RN)
1 32064-67-8/BI
(32064-67-8/RN)
1 392252-90-3/BI
(392252-90-3/RN)
1 392253-06-4/BI
(392253-06-4/RN)
1 396724-30-4/BI
(396724-30-4/RN)
1 4513-77-3/BI
(4513-77-3/RN)
1 459-04-1/BI
(459-04-1/RN)
1 476459-17-3/BI
(476459-17-3/RN)
1 476459-32-2/BI
(476459-32-2/RN)
1 50-00-0/BI
(50-00-0/RN)
1 521268-89-3/BI
(521268-89-3/RN)
1 53641-60-4/BI
(53641-60-4/RN)
1 539-44-6/BI
(539-44-6/RN)
1 5841-70-3/BI
(5841-70-3/RN)
1 59997-51-2/BI
(59997-51-2/RN)
1 616-45-5/BI
(616-45-5/RN)
1 62-53-3/BI
(62-53-3/RN)
1 63419-60-3/BI
(63419-60-3/RN)
1 664966-72-7/BI
(664966-72-7/RN)
1 68282-47-3/BI
(68282-47-3/RN)
1 80501-45-7/BI
(80501-45-7/RN)
1 805961-39-1/BI
(805961-39-1/RN)

1 848144-06-9/BI
(848144-06-9/RN)
1 858668-62-9/BI
(858668-62-9/RN)
1 858668-65-2/BI
(858668-65-2/RN)
1 858668-66-3/BI
(858668-66-3/RN)
1 858668-67-4/BI
(858668-67-4/RN)
1 858668-68-5/BI
(858668-68-5/RN)
1 858668-69-6/BI
(858668-69-6/RN)
1 858668-71-0/BI
(858668-71-0/RN)
1 858668-72-1/BI
(858668-72-1/RN)
1 858668-73-2/BI
(858668-73-2/RN)
1 858668-74-3/BI
(858668-74-3/RN)
1 858668-75-4/BI
(858668-75-4/RN)
1 858668-76-5/BI
(858668-76-5/RN)
1 858668-77-6/BI
(858668-77-6/RN)
1 858668-78-7/BI
(858668-78-7/RN)
1 858668-79-8/BI
(858668-79-8/RN)
1 858668-80-1/BI
(858668-80-1/RN)
1 858668-81-2/BI
(858668-81-2/RN)
1 858668-82-3/BI
(858668-82-3/RN)
1 858668-83-4/BI
(858668-83-4/RN)
1 858668-84-5/BI
(858668-84-5/RN)
1 858668-85-6/BI
(858668-85-6/RN)
1 858668-86-7/BI
(858668-86-7/RN)
1 858668-87-8/BI
(858668-87-8/RN)
1 858668-88-9/BI
(858668-88-9/RN)
1 858668-89-0/BI
(858668-89-0/RN)
1 858668-90-3/BI
(858668-90-3/RN)
1 858668-91-4/BI
(858668-91-4/RN)
1 858668-92-5/BI
(858668-92-5/RN)
1 858668-93-6/BI
(858668-93-6/RN)
1 858668-94-7/BI
(858668-94-7/RN)

```
             1 858668-95-8/BI
               (858668-95-8/RN)
             1 858668-96-9/BI
               (858668-96-9/RN)
             1 858668-98-1/BI
               (858668-98-1/RN)
             1 867-13-0/BI
               (867-13-0/RN)
             1 98-09-9/BI
               (98-09-9/RN)
             1 98-88-4/BI
               (98-88-4/RN)
             1 99280-85-0/BI
               (99280-85-0/RN)
L2          70 (100-39-0/BI OR 103-80-0/BI OR 1073-69-4/BI OR 108-69-0/BI OR
               110937-65-0/BI OR 16563-14-7/BI OR 175463-32-8/BI OR 1939-99-7/B
               I OR 214542-52-6/BI OR 214542-59-3/BI OR 285984-25-0/BI OR 32064
               -67-8/BI OR 392252-90-3/BI OR 392253-06-4/BI OR 396724-30-4/BI
               OR 4513-77-3/BI OR 459-04-1/BI OR 476459-17-3/BI OR 476459-32-2/
               BI OR 50-00-0/BI OR 521268-89-3/BI OR 53641-60-4/BI OR 539-44-6/
               BI OR 5841-70-3/BI OR 59997-51-2/BI OR 616-45-5/BI OR 62-53-3/BI
                OR 63419-60-3/BI OR 664966-72-7/BI OR 68282-47-3/BI OR 80501-45
               -7/BI OR 805961-39-1/BI OR 848144-06-9/BI OR 858668-62-9/BI OR
               858668-65-2/BI OR 858668-66-3/BI OR 858668-67-4/BI OR 858668-68-
               5/BI OR 858668-69-6/BI OR 858668-71-0/BI OR 858668-72-1/BI OR
               858668-73-2/BI OR 858668-74-3/BI OR 858668-75-4/BI OR 858668-76-
               5/BI OR 858668-77-6/BI OR 858668-78-7/BI OR 858668-79-8/BI OR
               858668-80-1/BI OR 858668-81-2/BI OR 858668-82-3/BI OR 858668-83-
               4/BI OR 858668-84-5/BI OR 858668-85-6/BI OR 858668-86-7/BI OR
               858668-87-8/BI OR 858668-88-9/BI OR 858

=> d sca

L2   70 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   Formaldehyde
MF   C H2 O
CI   COM


H2C=O


**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2   70 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   1H-Imidazole-5-propanoyl chloride, 2-phenyl-
MF   C12 H11 Cl N2 O
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
```

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclobutanecarbonitrile, 2-amino-
MF C5 H8 N2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenemethanesulfonamide, N-(6,7-dihydro-2-phenyl-5H-pyrrolo[1,2-a]imidazol-3-yl)-
MF C19 H19 N3 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-[2-(4-chlorophenyl)-2,4,5,6-tetrahydro-5-methylpyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro-
MF C20 H18 Cl F N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-[2-(4-chlorophenyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-4-fluoro-, hydrochloride (1:?)
MF C19 H16 Cl F N4 O . x Cl H



● x HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-(6,7-dihydro-2-phenyl-5H-pyrrolo[1,2-a]imidazol-3-yl)-4-fluoro-
MF C20 H18 F N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-(6,7-dihydro-2-phenyl-5H-pyrrolo[1,2-a]imidazol-3-yl)-
MF C20 H19 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenesulfonamide, N-[2-(4-chlorophenyl)-2,6-dihydro-4H-thieno[3,4-

c]pyrazol-3-yl]-N-(phenylsulfonyl)-
MF C23 H18 Cl N3 O4 S3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenemethanesulfonamide, N-[2-(4-chlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-
MF C20 H20 Cl N3 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenemethanesulfonamide, N-[2-(4-chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-
MF C18 H16 Cl N3 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenesulfonamide, N-[2-(1,1-dimethylethyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-
MF C15 H19 N3 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenesulfonamide, N-[2-(4-chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-
MF C17 H14 Cl N3 O2 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Imidazole-5-propanamide, N-(3,5-dimethylphenyl)-2-phenyl-
MF C20 H21 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Imidazole-5-propanamide, N,2-diphenyl-
MF C18 H17 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Pyrrolo[3,4-c]pyrazole-5(4H)-carboxylic acid,
    2-(4-chlorophenyl)-3-[[2-(4-fluorophenyl)acetyl]amino]-2,6-dihydro-,
    1,1-dimethylethyl ester
MF C24 H24 Cl F N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-[2-(4-chlorophenyl)-2,4,5,6,7,8-hexahydro-3-cycloheptapyrazolyl]-
MF C22 H22 Cl N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-[2-(1,1-dimethylethyl)-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl]-
MF C18 H23 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-[2-(4-chlorophenyl)-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl]-
MF C20 H18 Cl N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-[2-(4-chlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-4-fluoro-
MF C21 H19 Cl F N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 2,5-dichloro-N-[3-(2-phenyl-1H-imidazol-5-yl)propyl]-
MF C19 H17 Cl2 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[3-(2-phenyl-1H-imidazol-5-yl)propyl]-
MF C19 H19 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenepropanamide, N-[1-(1,1-dimethylethyl)-4-phenyl-1H-pyrazol-5-yl]-
MF C22 H25 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-[1-(1,1-dimethylethyl)-4-phenyl-1H-pyrazol-5-yl]-4-
    fluoro-
MF C21 H22 F N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Thiophenecarboxamide, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-
    pyrazol-5-yl]-
MF C19 H21 N3 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-4-fluoro-
MF C22 H24 F N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Imidazole-5-propanamide, 2-phenyl-
MF C12 H13 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propenoic acid, 3-[2-phenyl-1-(phenylmethyl)-1H-imidazol-4-yl]-, ethyl ester, (2E)-
MF C21 H20 N2 O2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 5H-Pyrrolo[1,2-a]imidazol-3-amine, 6,7-dihydro-2-phenyl-
MF C12 H13 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Pyrrolo[3,4-c]pyrazole-5(4H)-carboxylic acid, 3-amino-2-(4-chlorophenyl)-2,6-dihydro-, 1,1-dimethylethyl ester
MF C16 H19 Cl N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Cycloheptapyrazolamine, 2-(4-chlorophenyl)-2,4,5,6,7,8-hexahydro-
MF C14 H16 Cl N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Cyclopentapyrazolamine, 2-(1,1-dimethylethyl)-2,4,5,6-tetrahydro-
MF C10 H17 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Cyclopentapyrazolamine, 2-(4-chlorophenyl)-2,4,5,6-tetrahydro-
MF C12 H12 Cl N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4H-Thieno[3,4-c]pyrazol-3-amine, 2,6-dihydro-2-(4-methylphenyl)-
MF C12 H13 N3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-
MF C21 H23 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Imidazole-5-propanoic acid, 2-phenyl-
MF C12 H12 N2 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Pyrazol-5-amine, 1-(1,1-dimethylethyl)-4-phenyl-
MF C13 H17 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Imidazole-5-propanamine, 2-phenyl-
MF C12 H15 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-[2-(1,1-dimethylethyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-4-fluoro-
MF C17 H20 F N3 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenepropanamide, N-[2-(4-chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-
MF C20 H18 Cl N3 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-[2,6-dihydro-2-(4-methylphenyl)-4H-thieno[3,4-c]pyrazol-3-yl]-
MF C20 H19 N3 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-[2-(4-chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-
MF C19 H16 Cl N3 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN Benzamide, N-[2-(1,1-dimethylethyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-
MF C16 H19 N3 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Pyrazol-5-amine, 3-(1,1-dimethylethyl)-1-(4-methylphenyl)-
MF C14 H19 N3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4H-Thieno[3,4-c]pyrazol-3-amine, 2-(1,1-dimethylethyl)-2,6-dihydro-
MF C9 H15 N3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN 4H-Thieno[3,4-c]pyrazol-3-amine, 2-(4-chlorophenyl)-2,6-dihydro-
MF C11 H10 Cl N3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1-Pyrrolidinecarboxylic acid, 3-cyano-4-oxo-, 1,1-dimethylethyl ester
MF C10 H14 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Imidazole-5-propanoic acid, 2-phenyl-, ethyl ester
MF C14 H16 N2 O2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN 1H-Imidazole-4-carboxaldehyde, 2-phenyl-1-(phenylmethyl)-
MF C17 H14 N2 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclopentanecarbonitrile, 2-amino-
MF C6 H10 N2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1H-Imidazole-5-carboxaldehyde, 2-phenyl-
MF C10 H8 N2 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2H-Indazol-3-amine, 2-(4-chlorophenyl)-4,5,6,7-tetrahydro-
MF C13 H14 Cl N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Pentanenitrile, 4,4-dimethyl-3-oxo-
MF C7 H11 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetonitrile, α-amino-, hydrochloride (1:1)
MF C8 H8 N2 . Cl H



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Hydrazine, (1,1-dimethylethyl)-
MF C4 H12 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Thiophenecarbonitrile, tetrahydro-4-oxo-
MF C5 H5 N O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetonitrile, α-formyl-
MF C9 H7 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclohexanecarbonitrile, 2-oxo-
MF C7 H9 N O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenemethanesulfonyl chloride
MF C7 H7 Cl O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Hydrazine, (4-chlorophenyl)-
MF C6 H7 Cl N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Acetic acid, 2-(diethoxyphosphinyl)-, ethyl ester
MF C8 H17 O5 P
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Pyrrolidinone
MF C4 H7 N O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Hydrazine, (4-methylphenyl)-
MF C7 H10 N2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetyl chloride, 4-fluoro-
MF C8 H6 Cl F O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenamine, 3,5-dimethyl-
MF C8 H11 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetyl chloride
MF C8 H7 Cl O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzene, (bromomethyl)-
MF C7 H7 Br
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzoyl chloride
MF C7 H5 Cl O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenesulfonyl chloride
MF C6 H5 Cl O2 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 70 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenamine
MF C6 H7 N
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> 1
1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> 1
1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=>
Uploading C:\Documents and Settings\vrodriguezgarcia\My Documents\e-Red Folder\10584280\L1.str





ring nodes :
1 2 3 4 5 6 7 8

```
ring bonds :
1-2  1-5  2-3  3-4  3-6  4-5  4-8  6-7  7-8
exact/norm bonds :
1-2  1-5  2-3  3-4  3-6  4-5  4-8  6-7  7-8
isolated ring systems :
containing 1 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom



L3      STRUCTURE UPLOADED

=> s sam sss l3
SAMPLE SEARCH INITIATED 09:55:12 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    41782 TO ITERATE

  4.8% PROCESSED     2000 ITERATIONS                              29 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       823423 TO   847857
PROJECTED ANSWERS:           10640 TO    13592

L4           29 SEA SSS SAM L3

=> d sca

L4   29 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   2H-Indazole-2-acetamide, 4,5,6,7-tetrahydro-5-methyl-N-(4-methylphenyl)-
MF   C17 H21 N3 O
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4   29 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   2H-Indazole-3-carbonitrile, 2-[5-chloro-1-(2-cyanoethyl)-1,6-dihydro-6-oxo-
     2-pyridinyl]-4,5,6,7-tetrahydro-
MF   C16 H14 Cl N5 O
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Pyridinecarboxylic acid, 3-chloro-6-(3,5-dichloro-4,5,6,7-tetrahydro-2H-indazol-2-yl)-, ethyl ester
MF C15 H14 Cl3 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2H-Indazole, 3-chloro-2-[3,5-dichloro-6-[1-(2-propen-1-yloxy)ethyl]-2-pyridinyl]-5-fluoro-4,5,6,7-tetrahydro-
MF C17 H17 Cl3 F N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzoic acid, 2-bromo-5-(4,5,6,7-tetrahydro-3-methoxy-2H-indazol-2-yl)-, 1-methylethyl ester
MF C18 H21 Br N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4-Piperidinecarboxamide, 1-[(4-methoxyphenyl)sulfonyl]-N-(2,4,5,6-tetrahydro-2-methyl-3-cyclopentapyrazolyl)-
MF C20 H26 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Pyridinecarbonitrile, 6-(3-chloro-4,5,6,7-tetrahydro-5-hydroxy-2H-indazol-2-yl)-5-fluoro-1,2-dihydro-1-(methoxymethyl)-2-thioxo-
MF C15 H14 Cl F N4 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 29 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Pyridinepropanoic acid, α,3-dichloro-6-(3,5-dichloro-4,5,6,7-tetrahydro-2H-indazol-2-yl)-, ethyl ester
MF C17 H17 Cl4 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>
Uploading C:\Documents and Settings\vrodriguezgarcia\My Documents\e-Red Folder\10584280\L5.str





chain nodes :
12 13 14 15 16 19 20
ring nodes :
1 2 3 4 5 6 7 8
chain bonds :
1-19 2-12 12-13 13-14 13-15 14-16 19-20
ring bonds :
1-2 1-5 2-3 3-4 3-6 4-5 4-8 6-7 7-8
exact/norm bonds :
1-2 1-5 1-19 2-3 2-12 3-4 3-6 4-5 4-8 6-7 7-8 12-13 13-15 14-16 19-20

exact bonds :
13-14
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 12:CLASS 13:CLASS
14:CLASS 15:CLASS 16:Atom 19:CLASS 20:Atom

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s sam sss l5
SAMPLE SEARCH INITIATED 10:44:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1004 TO ITERATE

100.0% PROCESSED 1004 ITERATIONS 16 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 18180 TO 21980
PROJECTED ANSWERS: 80 TO 560

L6 16 SEA SSS SAM L5

=> d sca

L6 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C21 H26 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, 2-chloro-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C20 H18 Cl N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzenepropanamide, 3,4-dimethoxy-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C23 H25 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclopropanecarboxamide, 2,2-dichloro-1-methyl-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C17 H17 Cl2 N3 O



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 4-cyano-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C20 H16 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 4-(4-morpholinylsulfonyl)-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C23 H24 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-[(methylphenylamino)sulfonyl]-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C26 H24 N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C23 H26 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propenamide, 3-[4-(4-morpholinylsulfonyl)phenyl]-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C25 H26 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3(2H)-Benzoxazolebutanamide, 6-nitro-2-oxo-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-

MF C23 H21 N5 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C25 H28 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 4-chloro-3-nitro-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C19 H15 Cl N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN 4-Piperidinecarboxamide, 1-[(4-methoxyphenyl)sulfonyl]-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C25 H28 N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C24 H25 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3(2H)-Benzoxazolebutanamide, 2-oxo-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C23 H22 N4 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 16 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cyclopentanecarboxamide, N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C18 H21 N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> 1
1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s full sss l5
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 10:48:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 19214 TO ITERATE

100.0% PROCESSED 19214 ITERATIONS 291 ANSWERS
SEARCH TIME: 00.00.02

L7 291 SEA SSS FUL L5

=> s l7 and L2
L8 3 L7 AND L2

=> d sca

L8 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-[2-(4-chlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-4-fluoro-
MF C21 H19 Cl F N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-[2-(4-chlorophenyl)-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl]-
MF C20 H18 Cl N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 3 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzeneacetamide, N-[2-(4-chlorophenyl)-2,4,5,6,7,8-hexahydro-3-cycloheptapyrazolyl]-
MF C22 H22 Cl N3 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file zcaplus
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 233.88 | 241.25

FILE 'ZCAPLUS' ENTERED AT 10:51:43 ON 15 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 15 Jun 2009 VOL 150 ISS 25
FILE LAST UPDATED: 14 Jun 2009 (20090614/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

ZCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l8
L9 1 L8

=> d sca

L9 1 ANSWERS ZCAPLUS COPYRIGHT 2009 ACS on STN
IC ICM A61K031-415
ICS A61K031-416; A61K031-4162; A61K031-4164; A61K031-4155; A61K031-417; A61K031-4172; A61K031-4184; A61K045-00; A61P001-04; A61P009-06; A61P009-12; A61P011-02; A61P011-06; A61P013-00; A61P015-00; A61P015-10; A61P015-12; A61P025-08; A61P025-16
CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
TI Preparation of pyrazole, fused pyrazole, and imidazole derivatives as preventives and/or therapeutic agents for disease in which mitochondrial benzodiazepine receptor participates
ST pyrazole prepn prevention treatment stress related disease; fused pyrazole prepn prevention treatment stress related disease; imidazole prepn prevention treatment stress related disease; mitochondrial benzodiazepine receptor affinity pyrazole imidazole prepn; central nervous system disease prevention treatment pyrazole imidazole prepn; respiratory disease prevention treatment pyrazole imidazole prepn; digestive tract disease

prevention treatment pyrazole imidazole prepn

IT Anxiety
Asthma
Central nervous system, disease
Digestive tract, disease
Epilepsy
Nervous system agents
Respiratory system, disease
Sleep disorders
(attributable to stress; preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

IT Mental and behavioral disorders
(depression, attributable to stress; preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

IT Intestine, disease
(irritable bowel syndrome, attributable to stress; preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

IT Benzodiazepine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(peripheral-type; preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

IT Antiasthmatics
Anticonvulsants
Antidepressants
Anxiolytics
Stress, animal
(preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

IT 110937-65-0P, Ethyl 3-(2-phenyl-1H-imidazol-4-yl)propanoate
285984-25-0P, 1-(4-Methylphenyl)-3-tert-butylpyrazole-5-amine
805961-39-1P, 3-(2-Phenyl-1H-imidazol-4-yl)propanoic acid 858668-71-0P, Ethyl (2E)-3-(1-benzyl-2-phenyl-1H-imidazol-4-yl)-2-propenoate
858668-72-1P, 3-(2-Phenyl-1H-imidazol-4-yl)propanamide 858668-93-6P, N-[2-(4-Chlorophenyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2-(4-fluorophenyl)acetamide hydrochloride
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

IT 63419-60-3P, 2-(4-Chlorophenyl)-4,5,6,7-tetrahydro-2H-indazole-3-amine
214542-52-6P, 2-(4-Chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazole-3-amine 214542-59-3P, 2-tert-Butyl-2,6-dihydro-4H-thieno[3,4-c]pyrazole-3-amine 392252-90-3P, N-(2-tert-Butyl-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl)benzamide 392253-06-4P, N-[2-(4-Chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-2-phenylacetamide 396724-30-4P, N-[2-(4-Methylphenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-2-phenylacetamide 476459-17-3P, N-[2-(4-Chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-3-phenylpropanamide 476459-32-2P, N-(2-tert-Butyl-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl)-2-(4-fluorophenyl)acetamide 521268-89-3P, 3-(2-Phenyl-1H-imidazol-4-yl)-1-propanamine 664966-72-7P, 1-tert-Butyl-4-phenyl-1H-pyrazole-5-amine 848144-06-9P, N-[3-tert-Butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]benzamide
858668-62-9P, 2-(4-Methylphenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazole-3-amine 858668-65-2P, 2-(4-Chlorophenyl)-2,4,5,6-

tetrahydrocyclopenta[c]pyrazole-3-amine 858668-66-3P, 2-tert-Butyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-amine 858668-67-4P, 2-(4-Chlorophenyl)-2,4,5,6,7,8-hexahydrocyclohepta[c]pyrazole-3-amine 858668-68-5P, 3-Amino-2-(4-chlorophenyl)-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazole-5-carboxylic acid tert-butyl ester 858668-69-6P, 2-Phenyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole-3-amine 858668-73-2P, N-[3-tert-Butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-(4-fluorophenyl)acetamide 858668-74-3P, N-[3-tert-Butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-thiophenecarboxamide 858668-75-4P, N-[1-tert-Butyl-4-phenyl-1H-pyrazol-5-yl]-2-(4-fluorophenyl)acetamide 858668-76-5P, N-[1-tert-Butyl-4-phenyl-1H-pyrazol-5-yl]-3-phenylpropanamide 858668-77-6P, N-[3-(2-Phenyl-1H-imidazol-4-yl)propyl]benzamide 858668-78-7P, 2,5-Dichloro-N-[3-(2-phenyl-1H-imidazol-4-yl)propyl]benzamide 858668-79-8P, N-[2-(4-Chlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-2-(4-fluorophenyl)acetamide 858668-80-1P, N-[2-(4-Chlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-2-phenylacetamide 858668-81-2P, N-(2-tert-Butyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-2-phenylacetamide 858668-82-3P, N-[2-(4-Chlorophenyl)-2,4,5,6,7,8-hexahydrocyclohepta[c]pyrazol-3-yl]-2-phenylacetamide 858668-83-4P, 2-(4-Chlorophenyl)-3-[[(4-fluorophenyl)acetyl]amino]-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazole-5-carboxylic acid tert-butyl ester 858668-84-5P, N-Phenyl-3-(2-phenyl-1H-imidazol-4-yl)propanamide 858668-85-6P, N-(3,5-Dimethylphenyl)-3-(2-phenyl-1H-imidazol-4-yl)propanamide 858668-86-7P, N-[2-(4-Chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]benzenesulfonamide 858668-87-8P, N-(2-tert-Butyl-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl)benzenesulfonamide 858668-88-9P, N-[2-(4-Chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-1-phenylmethanesulfonamide 858668-89-0P, N-[2-(4-Chlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-1-phenylmethanesulfonamide 858668-90-3P, N-[2-(4-Chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-N-(phenylsulfonyl)benzenesulfonamide 858668-91-4P, 2-Phenyl-N-(2-phenyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)acetamide 858668-92-5P, 2-(4-Fluorophenyl)-N-(2-phenyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)acetamide 858668-94-7P, N-[2-(4-Chlorophenyl)-5-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2-(4-fluorophenyl)acetamide 858668-95-8P, 1-Phenyl-N-(2-phenyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)methanesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

IT 50-00-0, Formaldehyde, reactions 62-53-3, Aniline, reactions 98-09-9, Benzenesulfonyl chloride 98-88-4, Benzoyl chloride 100-39-0, Benzyl bromide 103-80-0, Phenylacetyl chloride 108-69-0, 3,5-Dimethylaniline 459-04-1, (4-Fluorophenyl)acetyl chloride 539-44-6, 4-Methylphenylhydrazine 616-45-5, 2-Pyrrolidinone 867-13-0, Ethyl (diethoxyphosphoryl)acetate 1073-69-4, 4-Chlorophenylhydrazine 1939-99-7, Benzylsulfonyl chloride 4513-77-3, 2-Oxocyclohexane-1-carbonitrile 5841-70-3, 3-Oxo-2-phenylpropanenitrile 16563-14-7, 4-Oxotetrahydrothiophene-3-carbonitrile 32064-67-8, tert-Butylhydrazine 53641-60-4, 2-Amino-2-phenylacetonitrile hydrochloride 59997-51-2, 4,4-Dimethyl-3-oxopentanenitrile 68282-47-3, 4-Formyl-2-phenylimidazole 80501-45-7,

2-Aminocyclopentane-1-carbonitrile 175463-32-8,
1-tert-Butoxycarbonyl-4-oxopyrrolidine-3-carbonitrile 858668-96-9,
2-Aminocyclobutane-1-carbonitrile 858668-98-1,
3-(2-Phenyl-1H-imidazol-4-yl)propanoyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

IT 99280-85-0P, 1-Benzyl-4-formyl-2-phenylimidazole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

ALL ANSWERS HAVE BEEN SCANNED

=> d ibib

L9 ANSWER 1 OF 1 ZCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:612085 ZCAPLUS
DOCUMENT NUMBER: 143:133368
TITLE: Preparation of pyrazole, fused pyrazole, and imidazole derivatives as preventives and/or therapeutic agents for disease in which mitochondrial benzodiazepine receptor participates
INVENTOR(S): Ohmoto, Kazuyuki; Kato, Masashi; Katsumata, Seishi; Manako, Junichiro
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063241	A1	20050714	WO 2004-JP19753	20041224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1698335	A1	20060906	EP 2004-808103	20041224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
US 20080249154	A1	20081009	US 2006-584280	20060626
PRIORITY APPLN. INFO.:			JP 2003-433417 A	20031226
			WO 2004-JP19753 W	20041224

OTHER SOURCE(S): MARPAT 143:133368
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s L7
L10             5 L7

=> s l7 not l9
                5 L7
L11             4 L7 NOT L9

=> d ibib hitstr 1-4
THE ESTIMATED COST FOR THIS REQUEST IS 15.56 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L11  ANSWER 1 OF 4  ZCAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2009:493013  ZCAPLUS
DOCUMENT NUMBER:          150:423178
TITLE:                    Preparation of pyrazoles, oxazoles, and other
                          nitrogen-containing heterocyclic compounds as
                          therapeutic cannabinoid receptor ligands
INVENTOR(S):              Carroll, William A.; Dart, Michael J.; Perez-Medrano,
                          Arturo; Nelson, Derek W.; Li, Tongmei; Peddi, Sridhar;
                          Frost, Jennifer; Kolasa, Teodozyj; Liu, Bo; Latshaw,
                          Steven P.; Wang, Xueqing
PATENT ASSIGNEE(S):       Abbott Laboratories, USA
SOURCE:                   U.S. Pat. Appl. Publ., 56pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
     US 20090105306       A1    20090423    US 2008-246808          20081007
     WO 2009048936        A1    20090416    WO 2008-US79182         20081008
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                       US 2007-979653P     P  20071012
                                             US 2008-246808      A  20081007

IT   1140917-70-9P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of pyrazoles, oxazoles, and other nitrogen-containing
heterocyclic
        compds. as therapeutic cannabinoid receptor ligands)
RN   1140917-70-9  ZCAPLUS
CN   Benzamide, 2-methoxy-N-[2,4,5,6-tetrahydro-2-[[(2R)-tetrahydro-2-
     furanyl]methyl]-3-cyclopentapyrazolyl]-5-(trifluoromethyl)-  (CA INDEX
     NAME)

Absolute stereochemistry.
```



L11 ANSWER 2 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:455179 ZCAPLUS
DOCUMENT NUMBER: 150:423175
TITLE: Preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compounds as therapeutic cannabinoid receptor ligands
INVENTOR(S): Carroll, William A.; Meyer, Michael D.; Perez-Medrano, Arturo; Dart, Michael J.; Nelson, Derek W.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 119pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009048936	A1	20090416	WO 2008-US79182	20081008
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20090105306	A1	20090423	US 2008-246808	20081007
PRIORITY APPLN. INFO.:			US 2007-979653P	P 20071012
			US 2008-246808	A 20081007

OTHER SOURCE(S): MARPAT 150:423175
IT 1140917-70-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic
compds. as therapeutic cannabinoid receptor ligands)
RN 1140917-70-9 ZCAPLUS
CN Benzamide, 2-methoxy-N-[2,4,5,6-tetrahydro-2-[[(2R)-tetrahydro-2-furanyl]methyl]-3-cyclopentapyrazolyl]-5-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:538227 ZCAPLUS
DOCUMENT NUMBER: 146:521791
TITLE: Preparation of phenylpyrazole derivatives as P2X7 receptor antagonists
INVENTOR(S): Carroll, William A.; Perez-Medrano, Arturo; Li, Tongmei
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007056091	A2	20070518	WO 2006-US42867	20061102
WO 2007056091	A3	20070712		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
CA 2628260	A1	20070518	CA 2006-2628260	20061102
EP 1963275	A2	20080903	EP 2006-836830	20061102
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009514952	T	20090409	JP 2008-540080	20061102
US 20070259920	A1	20071108	US 2006-593773	20061107
MX 2008006015	A	20080522	MX 2008-6015	20080508
CN 101304975	A	20081112	CN 2006-80041673	20080508
PRIORITY APPLN. INFO.:			US 2005-734938P P	20051109

OTHER SOURCE(S): CASREACT 146:521791; MARPAT 146:521791

IT 936840-77-6P, N-[2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]nicotinamide 936840-80-1P, N-[2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-2-methylnicotinamide 936840-91-4P, N-[2-(2,3-Dichlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-2-methylnicotinamide 936840-96-9P, N-[2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-2-phenoxynicotinamide 936840-98-1P, N-[2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-2-phenoxybenzamide 936841-00-8P, 2-(3-Chlorophenoxy)-N-[2-(2,3-dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]nicotinamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)

RN 936840-77-6 ZCAPLUS

CN 3-Pyridinecarboxamide, N-[2-(2,3-dichlorophenyl)-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl]- (CA INDEX NAME)



RN 936840-80-1 ZCAPLUS

CN 3-Pyridinecarboxamide, N-[2-(2,3-dichlorophenyl)-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl]-2-methyl- (CA INDEX NAME)



RN 936840-91-4 ZCAPLUS

CN 3-Pyridinecarboxamide, N-[2-(2,3-dichlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-2-methyl- (CA INDEX NAME)



RN 936840-96-9 ZCAPLUS
CN 3-Pyridinecarboxamide, N-[2-(2,3-dichlorophenyl)-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl]-2-phenoxy- (CA INDEX NAME)



RN 936840-98-1 ZCAPLUS
CN Benzamide, N-[2-(2,3-dichlorophenyl)-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl]-2-phenoxy- (CA INDEX NAME)



RN 936841-00-8 ZCAPLUS
CN 3-Pyridinecarboxamide, 2-(3-chlorophenoxy)-N-[2-(2,3-dichlorophenyl)-2,4,5,6-tetrahydro-3-cyclopentapyrazolyl]- (CA INDEX NAME)



L11 ANSWER 4 OF 4 ZCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:421288 ZCAPLUS
DOCUMENT NUMBER: 148:403163
TITLE: Reactions of isatoic anhydride with some aminoheterocycles
AUTHOR(S): Strakovs, A.; Avotins, F.; Strakova, I.; Bizdena, E.; Petrova, M.
CORPORATE SOURCE: Faculty of Material Science and Applied Chemistry, Riga Technical University, Riga, LV 1048, Latvia
SOURCE: Rigas Tehniskas Universitates Zinatniskie Raksti, Serija 1: Materialzinatne un Lietiska Kimija (2006), 12, 76-79
CODEN: RTUZAL; ISSN: 1407-7353
PUBLISHER: Izdevnieciba RTU
DOCUMENT TYPE: Journal
LANGUAGE: Latvian
OTHER SOURCE(S): CASREACT 148:403163
IT 1016638-24-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of heterocycle-substituted anthranilic acid amides via amidation reactions of isatoic anhydride with aminoheterocycles)
RN 1016638-24-6 ZCAPLUS
CN Benzamide, 2-amino-N-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-2-(4-quinazolinyl)-2H-indazol-3-yl]- (CA INDEX NAME)



=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	17.86	259.11

FILE 'REGISTRY' ENTERED AT 11:00:35 ON 15 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2009 HIGHEST RN 1157585-76-6
DICTIONARY FILE UPDATES: 14 JUN 2009 HIGHEST RN 1157585-76-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d sca k7
YOU HAVE REQUESTED DATA FROM FILE 'ZCAPLUS' - CONTINUE? (Y)/N:n

=> d sca l7

L7 291 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C23 H26 N4 O3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L7 291 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 10(9H)-Acridineacetamide, 9-oxo-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C27 H22 N4 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L7 291 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-[(2-methyl-4-thiazolyl)methoxy]-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C24 H22 N4 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L7 291 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 3-Thiophenecarboxamide, N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C17 H15 N3 O S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L7 291 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3,4-dimethoxy-5-(2-propen-1-yl)-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C24 H25 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L7 291 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzamide, 3-[(methylsulfonyl)methyl]-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C21 H21 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L7 291 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1-Phthalazinecarboxamide, 3,4-dihydro-4-oxo-3-phenyl-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
MF C27 H21 N5 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> sav temp l7 10584280/A
10584280/A IS NOT A VALID SAVED NAME
Enter the name you wish to use for the saved query,
answer set, or L-number list. The name must:
1. Begin with a letter,
2. Have 1-12 characters,
3. Contain only letters (A-Z) and numbers (0-9),
4. End with /Q for a query (search profile,
structure, or screen set), /A for an answer
set, or /L for an L-number list.
5. Not already be in use as a saved name,
6. Not be END, SAV, SAVE, SAVED
7. Not have the form of an L-number (Lnnn).
ENTER NAME OR (END):sav temp l7 S10584280/A
SAV TEMP L7 S10584280/A IS NOT A VALID SAVED NAME
Enter the name you wish to use for the saved query,
answer set, or L-number list. The name must:
1. Begin with a letter,
2. Have 1-12 characters,
3. Contain only letters (A-Z) and numbers (0-9),
4. End with /Q for a query (search profile,
structure, or screen set), /A for an answer
set, or /L for an L-number list.
5. Not already be in use as a saved name,
6. Not be END, SAV, SAVE, SAVED
7. Not have the form of an L-number (Lnnn).
ENTER NAME OR (END):sav temp S10584280/l7
SAV TEMP S10584280/L7 IS NOT A VALID SAVED NAME
Enter the name you wish to use for the saved query,
answer set, or L-number list. The name must:
1. Begin with a letter,
2. Have 1-12 characters,
3. Contain only letters (A-Z) and numbers (0-9),
4. End with /Q for a query (search profile,
structure, or screen set), /A for an answer
set, or /L for an L-number list.
5. Not already be in use as a saved name,
6. Not be END, SAV, SAVE, SAVED
7. Not have the form of an L-number (Lnnn).
ENTER NAME OR (END):end

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	48.48	307.59

FILE 'REGISTRY' ENTERED AT 12:01:14 ON 15 JUN 2009

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2009 HIGHEST RN 1157585-76-6

DICTIONARY FILE UPDATES: 14 JUN 2009 HIGHEST RN 1157585-76-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> sav l7 S10584280/A

=> d sav

NAME	CREATED	NOTES/TITLE
ALL063719/A	28 MAY 2009	101 ANSWERS IN FILE REGISTRY
A8150091AND4/A	22 MAY 2009	29777 ANSWERS IN FILE REGISTRY
FULL11815009/A	22 MAY 2009	56126 ANSWERS IN FILE REGISTRY
FULL11949402/A	27 MAY 2009	287 ANSWERS IN FILE REGISTRY
HY11815009/A	22 MAY 2009	1405 ANSWERS IN FILE REGISTRY
HY211815009/A	22 MAY 2009	348 ANSWERS IN FILE REGISTRY
L35SUB949402/A	28 MAY 2009	137 ANSWERS IN FILE REGISTRY
S10584280/A	15 JUN 2009	291 ANSWERS IN FILE REGISTRY

=> d his

     (FILE 'HOME' ENTERED AT 09:46:52 ON 15 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 09:48:09 ON 15 JUN 2009

     FILE 'STNGUIDE' ENTERED AT 09:49:34 ON 15 JUN 2009

     FILE 'ZCAPLUS' ENTERED AT 09:49:47 ON 15 JUN 2009
                E US2006-584280/APPS
L1   1 S US2006-584280/APPS
                SEL RN

     FILE 'REGISTRY' ENTERED AT 09:51:11 ON 15 JUN 2009
L2   70 S E1-E70
L3   STRUCTURE UPLOADED
L4   29 S SAM SSS L3
L5   STRUCTURE UPLOADED
L6   16 S SAM SSS L5
L7   291 S FULL SSS L5
L8   3 S L7 AND L2

     FILE 'ZCAPLUS' ENTERED AT 10:51:43 ON 15 JUN 2009
L9   1 S L8
L10   5 S L7
L11   4 S L7 NOT L9

     FILE 'REGISTRY' ENTERED AT 11:00:35 ON 15 JUN 2009

     FILE 'REGISTRY' ENTERED AT 12:01:14 ON 15 JUN 2009
                SAV L7 S10584280/A

```
=> exit
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      1.92     309.51

STN INTERNATIONAL LOGOFF AT 12:03:53 ON 15 JUN 2009


Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAVXR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  DEC 01  ChemPort single article sales feature unavailable
 NEWS  3  APR 03  CAS coverage of exemplified prophetic substances
                  enhanced
 NEWS  4  APR 07  STN is raising the limits on saved answers
 NEWS  5  APR 24  CA/CAplus now has more comprehensive patent assignee
                  information
 NEWS  6  APR 26  USPATFULL and USPAT2 enhanced with patent
                  assignment/reassignment information
 NEWS  7  APR 28  CAS patent authority coverage expanded
 NEWS  8  APR 28  ENCOMPLIT/ENCOMPLIT2 search fields enhanced
 NEWS  9  APR 28  Limits doubled for structure searching in CAS
                  REGISTRY
 NEWS 10  MAY 08  STN Express, Version 8.4, now available
 NEWS 11  MAY 11  STN on the Web enhanced
 NEWS 12  MAY 11  BEILSTEIN substance information now available on
                  STN Easy
 NEWS 13  MAY 14  DGENE, PCTGEN and USGENE enhanced with increased
                  limits for exact sequence match searches and
                  introduction of free HIT display format
 NEWS 14  MAY 15  INPADOCDB and INPAFAMDB enhanced with Chinese legal
                  status data
 NEWS 15  MAY 28  CAS databases on STN enhanced with NANO super role in
                  records back to 1992
 NEWS 16  JUN 01  CAS REGISTRY Source of Registration (SR) searching
                  enhanced on STN

 NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
              AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.
```

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:45:35 ON 15 JUN 2009

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 12:46:05 ON 15 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2009 HIGHEST RN 1157585-76-6
DICTIONARY FILE UPDATES: 14 JUN 2009 HIGHEST RN 1157585-76-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d sav

NAME	CREATED	NOTES/TITLE
ALL063719/A	28 MAY 2009	101 ANSWERS IN FILE REGISTRY
A8150091AND4/A	22 MAY 2009	29777 ANSWERS IN FILE REGISTRY
FULL11815009/A	22 MAY 2009	56126 ANSWERS IN FILE REGISTRY
FULL11949402/A	27 MAY 2009	287 ANSWERS IN FILE REGISTRY
HY11815009/A	22 MAY 2009	1405 ANSWERS IN FILE REGISTRY
HY211815009/A	22 MAY 2009	348 ANSWERS IN FILE REGISTRY
L35SUB949402/A	28 MAY 2009	137 ANSWERS IN FILE REGISTRY
S10584280/A	15 JUN 2009	291 ANSWERS IN FILE REGISTRY

=> activate S10584280/A
L1 STR
L2 291 SEA FILE=REGISTRY SSS FUL L1

=> d sca

L2 291 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN INDEX NAME NOT YET ASSIGNED
MF C23 H27 N5 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> l2 not CAPLUS/LC
L2 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.96	1.18

FILE 'REGISTRY' ENTERED AT 12:47:21 ON 15 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2009 HIGHEST RN 1157585-76-6
DICTIONARY FILE UPDATES: 14 JUN 2009 HIGHEST RN 1157585-76-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> l2 not CAPLUS/LC
L2 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

```
=> l2 not caplus/LC
L2 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l2
SAMPLE SEARCH INITIATED 12:48:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1004 TO ITERATE

100.0% PROCESSED     1004 ITERATIONS                                 16 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         18180 TO    21980
PROJECTED ANSWERS:               80 TO      560

L3           16 SEA SSS SAM L1

=> s l2 not CAPLUS/LC
      66947693 CAPLUS/LC
L4          280 L2 NOT CAPLUS/LC

=> s l2 not l4
L5           11 L2 NOT L4

=> d sca

L5   11 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   Benzeneacetamide, N-[2-(4-chlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-
     yl]-4-fluoro-
MF   C21 H19 Cl F N3 O
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file zcaplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 7.75       8.93

FILE 'ZCAPLUS' ENTERED AT 12:50:28 ON 15 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 15 Jun 2009 VOL 150 ISS 25
FILE LAST UPDATED: 14 Jun 2009 (20090614/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

ZCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s ;5
ENTER LOGIC EXPRESSION, QUERY NAME, OR (END):end
SEARCH ENDED BY USER

5 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l5
L6 5 L5

=> d sca

L6 5 ANSWERS ZCAPLUS COPYRIGHT 2009 ACS on STN
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
TI Preparation of pyrazoles, oxazoles, and other nitrogen-containing
heterocyclic compounds as therapeutic cannabinoid receptor ligands
ST nitrogen contg heterocycle prepn therapeutic cannabinoid receptor ligand;
pain treatment nitrogen contg heterocycle cannabinoid receptor ligand
IT Immune disease
(cancer of immune system; preparation of pyrazoles, oxazoles, and other
nitrogen-containing heterocyclic compds. as therapeutic cannabinoid
receptor ligands)
IT Pain
(inflammatory pain; preparation of pyrazoles, oxazoles, and other
nitrogen-containing heterocyclic compds. as therapeutic cannabinoid
receptor ligands)
IT Pain
(neuropathic pain; preparation of pyrazoles, oxazoles, and other
nitrogen-containing heterocyclic compds. as therapeutic cannabinoid
receptor ligands)
IT Analgesics
Anti-inflammatory agents
Antidiabetic agents

Antiobesity agents
Antitumor agents
Cardiovascular agents
Cardiovascular disease
Diabetes mellitus
Drug delivery systems
Human
Immune disease
Immunomodulators
Inflammation
Nervous system, disease
Nervous system agents
Neuroprotective agents
Obesity
Pain
Prophylaxis
Respiratory system agents
Respiratory system disease
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)

IT Cannabinoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type CB2; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)

IT 371-62-0P, 2-Fluoroethanol 1140917-43-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)

IT 1140917-13-0P 1140917-16-3P 1140917-18-5P 1140917-19-6P
1140917-20-9P 1140917-22-1P 1140917-24-3P 1140917-27-6P
1140917-29-8P 1140917-32-3P 1140917-34-5P 1140917-37-8P
1140917-41-4P 1140917-48-1P 1140917-49-2P 1140917-53-8P
1140917-54-9P 1140917-55-0P 1140917-56-1P 1140917-57-2P
1140917-58-3P 1140917-59-4P 1140917-60-7P 1140917-61-8P
1140917-62-9P 1140917-63-0P 1140917-64-1P 1140917-65-2P
1140917-66-3P 1140917-67-4P 1140917-68-5P 1140917-71-0P
1140917-75-4P 1140917-76-5P 1140917-77-6P 1140917-78-7P
1140917-79-8P 1140917-88-9P 1140917-89-0P 1140917-90-3P
1140917-91-4P 1140917-92-5P 1140917-94-7P 1140917-95-8P
1140918-00-8P 1140918-01-9P 1140918-02-0P 1140918-03-1P
1140918-04-2P 1140918-05-3P 1140918-06-4P 1140918-07-5P
1140918-08-6P 1140918-09-7P 1140918-10-0P 1140918-11-1P
1140918-12-2P 1140918-14-4P 1140918-15-5P 1140918-16-6P
1140918-18-8P 1140918-19-9P 1140918-24-6P 1140918-30-4P
1140918-36-0P 1140918-40-6P 1140918-41-7P 1140918-42-8P
1140918-43-9P 1140918-44-0P 1140918-45-1P 1140918-46-2P
1140918-47-3P 1140918-48-4P 1140918-49-5P 1140918-50-8P
1140918-51-9P 1140918-52-0P 1140918-54-2P 1140918-57-5P
1140918-59-7P 1140918-60-0P 1140918-61-1P 1140918-66-6P
1140918-67-7P 1140918-68-8P 1140918-69-9P 1140918-70-2P
1140918-71-3P 1140918-72-4P 1140918-73-5P 1140918-74-6P
1140918-75-7P 1140918-78-0P 1140918-79-1P 1140918-82-6P
1140918-83-7P 1140918-84-8P 1140918-85-9P 1141889-94-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid

receptor ligands)
IT 401892-81-7P, 3-(Pentafluorosulfanyl)benzoyl chloride 1140917-17-4P, 5-Cyclopropyl-3-[(tetrahydrofuran-2-yl)methyl]-1,3,4-thiadiazol-2(3H)-imine 1140917-33-4P, 5-Methyl-1-[(tetrahydrofuran-2-yl)methyl]pyridin-2(1H)-imine hydrobromide 1140917-39-0P 1140917-47-0P, 2-Ethoxy-5-(trifluoromethyl)benzoyl chloride
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic
compds. as therapeutic cannabinoid receptor ligands)
IT 57-57-8, 2-Oxetanone 75-64-9, 2-Methylpropan-2-amine, reactions 75-89-8, 2,2,2-Trifluoroethanol 76-83-5 79-19-6, Thiosemicarbazide 98-59-9, 4-Methylbenzene-1-sulfonyl chloride 104-75-6, 2-Ethylhexan-1-amine 108-01-0, 2-(Dimethylamino)ethanol 109-85-3, 2-Methoxyethanamine 110-18-9, N,N,N',N'-Tetramethylethane-1,2-diamine 110-52-1, 1,4-Dibromobutane 110-80-5, 2-Ethoxyethanol 111-35-3, 3-Ethoxypropan-1-ol 124-68-5, 2-Amino-2-methylpropan-1-ol 134-11-2, 2-Ethoxybenzoic acid 359-13-7, 2,2-Difluoroethanol 406-34-8, 2-Fluoroethanamine 407-25-0, 2,2,2-Trifluoroacetic anhydride 430-50-2, 1-Fluoropropan-2-ol 533-67-5, (3S,4R)-3,4,5-Trihydroxypentanal 556-82-1, 3-Methylbut-2-en-1-ol 598-74-3, 3-Methylbutan-2-amine 616-24-0, 3-Pentanamine 657-05-6, 2-Chloro-5-(trifluoromethyl)benzoyl chloride 833-96-5, 3-(Pentafluorothio)benzoic acid 1120-56-5, Methylenecyclobutane 1192-30-9, 2-(Bromomethyl)tetrahydrofuran 1589-49-7, 3-Methoxypropan-1-ol 1603-41-4, 5-Methylpyridin-2-amine 2026-48-4, (S)-2-Amino-3-methylbutan-1-ol 2217-40-5, 1,2,3,4-Tetrahydronaphthalen-1-amine 2568-33-4, 3-Methylbutane-1,3-diol 2941-29-9, 2-Oxocyclopentanecarbonitrile 3433-90-7, 2-Methoxy-5-cyanobenzoyl chloride 3438-16-2, 5-Chloro-2-methoxybenzoic acid 3824-87-1, 2-Fluoropropan-1-ol 4088-84-0, 2-Fluoro-5-(trifluoromethyl)benzonitrile 4637-24-5 4864-01-1, 2-Methoxy-5-(trifluoromethyl)benzoic acid 5241-58-7, (S)-2-Amino-3-phenylpropanamide 5452-35-7, Cycloheptanamine 5469-26-1, 1-Bromo-3,3-dimethylbutan-2-one 5813-64-9, 2,2-Dimethylpropan-1-amine 6206-25-3 6321-23-9, 4-Methylcyclohexanamine 6914-76-7, 1-Methylcyclopropane-1-carboxylic acid 7202-43-9, (R)-(Tetrahydrofuran-2-yl)methylamine 7533-40-6, (S)-2-Amino-4-methylpentan-1-ol 7547-97-9 14445-54-6, (2S,3S)-2-Amino-3-methylpentanamide 15833-61-1, (Tetrahydrofuran-3-yl)methanol 16466-61-8 17342-08-4, (S)-5-(Hydroxymethyl)pyrrolidin-2-one 17397-24-9, (S)-Hex-5-en-2-ol 17397-29-4, (R)-Hex-5-en-2-ol 17430-98-7, (S)-1-Cyclohexylethanamine 17768-41-1, (Adamantylmethyl)amine 17869-77-1, Trimethyl(2-methyl-3-butyn-2-yloxy)silane 18162-48-6, tert-Butyldimethylsilyl chloride 21900-51-6, 2-Chloro-5-fluorobenzoyl chloride 22374-89-6, 4-Phenylbutan-2-amine 22415-59-4, ((R)-Tetrahydrofuran-2-yl)methanol 25015-63-8, 4,4,5,5-Tetramethyl-1,3,2-dioxaborolane 33252-26-5, 4-tert-Butylpyridin-2-amine 34723-82-5, 2-(Bromomethyl)tetrahydro-2H-pyran 39222-73-6, 2-Amino-5-tert-butyl-1,3,4-thiadiazole 40615-36-9 55809-36-4, 5-tert-Butylisoxazol-3-amine 56539-66-3, 3-Methoxy-3-methylbutan-1-ol 56663-76-4, 2,2-Dimethyl-3-butynoic acid 57203-01-7 57235-50-4, 5-Cyclopropyl-1,3,4-thiadiazol-2-amine 59997-51-2, 4,4-Dimethyl-3-oxopentanenitrile 62910-63-8, 2-Methoxy-5-bromobenzoyl chloride 64507-07-9, 2-Methoxy-5-(trifluoromethyl)benzoyl chloride 66673-40-3, (R)-5-(Hydroxymethyl)pyrrolidin-2-one 73522-42-6, ((1S,2R,5S)-6,6-Dimethylbicyclo[3.1.1]heptan-2-yl)methanamine 82560-12-1, 3-tert-Butyl-2H-pyrazol-5-amine 83306-84-7, (R)-Tetrahydrofuran-2-ol 89226-12-0, (S)-2-Amino-N-methyl-3,3-dimethylbutanamide 104641-59-0,

(S)-1-Methylpyrrolidin-3-ol 107496-54-8,
3,3-Difluorocyclobutanecarboxylic acid 108551-60-6,
5-Bromo-2,3-dihydrobenzofuran-7-carbonyl chloride 111857-74-0,
(S)-Tetrahydrofuran-2-ol 112245-13-3, (S)-2-Amino-3,3-dimethylbutan-1-ol
115029-23-7, 2-Fluoro-5-(trifluoromethyl)benzoic acid 116422-39-0,
(S)-2-Methoxypropan-1-ol 141699-55-0, tert-Butyl
3-hydroxyazetidine-1-carboxylate 154669-49-5, 4-Methylbenzenesulfonic
acid (S)-(2-oxo-1,3-oxazolidin-4-yl)methyl ester 165059-42-7,
(E)-2-(3-Methoxyprop-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
171243-30-4, 3-Fluoro-5-trifluoromethylbenzoyl chloride 172324-68-4
183616-18-4, 3-(Hydroxymethyl)cyclobutanone 207981-46-2,
2-Fluoro-5-(trifluoromethyl)benzoyl chloride 208173-19-7,
2-Fluoro-3-(trifluoromethyl)benzoyl chloride 240800-48-0,
2,3,5-Trifluorobenzoyl chloride 261763-03-5,
3-Chloro-2-fluoro-5-(trifluoromethyl)benzoyl chloride 261952-08-3,
2-Methyl-5-(trifluoromethyl)benzoyl chloride 277756-45-3,
1-(Trifluoromethyl)cyclobutanecarboxylic acid 277756-46-4,
1-(Trifluoromethyl)cyclopropanecarboxylic acid 472809-65-7,
2-Ethoxy-5-(trifluoromethyl)benzoic acid 773140-42-4 876747-18-1,
(R)-2-Fluoropropan-1-ol 889940-13-0,
3,3,3-Trifluoro-2,2-dimethylpropanoic acid 895157-70-7,
2,2,3,3-Tetrafluoro-1-methylcyclobutanecarbonyl chloride 944836-48-0,
2-Bromo-5-trifluoromethylbenzoyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic
compds. as therapeutic cannabinoid receptor ligands)

IT 6970-72-5P, 1-(Hydroxymethyl)cyclobutanol 13942-76-2P,
(2R,3S)-Pentane-1,2,3,5-tetraol 15833-63-3P,
(Tetrahydrofuran-3-yl)methyl 4-methylbenzenesulfonate 22415-60-7P,
4-Methylbenzenesulfonic acid (2R)-tetrahydrofuran-2-ylmethyl ester
29568-33-0P, 5-Chloro-2-methoxybenzoyl chloride 73089-93-7P,
1-(2-Hydroxyethyl)cyclopentanol 88485-78-3P,
3-(1-Methylcyclopropyl)-3-oxopropanenitrile 91547-59-0P,
(2R,3S)-2-(Hydroxymethyl)tetrahydrofuran-3-ol 95049-01-7P,
(2R,3S)-2-[[Bis(4-methoxyphenyl)(phenyl)methoxy]methyl]tetrahydrofuran-3-ol 97987-64-9P, 5-(1,1-Dimethylprop-2-ynyl)-1,3,4-thiadiazol-2-amine
114114-90-8P, 4-Methylbenzenesulfonic acid (2S)-tetrahydrofuran-2-ylmethyl ester 432509-85-8P, N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-5-chloro-2-methoxybenzamide 681128-39-2P 908269-41-0P,
5-(1-Methylcyclopropyl)-1,3,4-thiadiazol-2-amine 959600-77-2P,
[[(cis-3-Methoxycyclobutyl)methoxy]methyl]benzene 959600-78-3P,
(cis-3-Methoxycyclobutyl)methanol 959749-92-9P,
[[cis-3-[(Benzyloxy)methyl]cyclobutyl]oxy](tert-butyl)dimethylsilane
959749-93-0P, [cis-3-[(tert-Butyldimethylsilyl)oxy]cyclobutyl]methanol
1032464-60-0P, 5-[1-(Trifluoromethyl)cyclobutyl]-1,3,4-thiadiazol-2-amine
1034356-15-4P, (R)-Tetrahydrofuran-2-ylmethylcyanamide 1138162-60-3P
1140917-14-1P, 5-[1-(Trifluoromethyl)cyclopropyl]-1,3,4-thiadiazol-2-amine
1140917-15-2P 1140917-21-0P, 5-Chloro-2-methoxy-N-[5-(1-methylcyclopropyl)-1,3,4-thiadiazol-2-yl]benzamide 1140917-23-2P,
5-Chloro-N-[5-(1,1-dimethylprop-2-ynyl)-1,3,4-thiadiazol-2-yl]-2-methoxybenzamide 1140917-25-4P, 5-(2,2,3,3-Tetrafluoro-1-methylcyclobutyl)-1,3,4-thiadiazol-2-amine 1140917-26-5P,
5-Chloro-2-methoxy-N-[5-(2,2,3,3-tetrafluoro-1-methylcyclobutyl)-1,3,4-thiadiazol-2-yl]benzamide 1140917-28-7P 1140917-30-1P,
5-(2,2,2-Trifluoro-1,1-dimethylethyl)-1,3,4-thiadiazol-2-amine
1140917-31-2P 1140917-36-7P 1140917-38-9P 1140917-40-3P
1140917-42-5P, (R)-5-tert-Butyl-3-[(tetrahydrofuran-2-yl)methyl]oxazol-2(3H)-imine 1140917-44-7P, (R)-N-[3-tert-Butyl-1-[(tetrahydrofuran-2-yl)methyl]-1H-pyrazol-5-yl]-2,2,2-trifluoroethanamide 1140917-45-8P
1140917-46-9P 1140917-50-5P 1140917-51-6P 1140917-52-7P
1140917-69-6P, (S)-2-[(Tetrahydrofuran-2-yl)methyl]-2,4,5,6-

tetrahydrocyclopenta[c]pyrazol-3-amine 1140917-70-9P
1140917-72-1P, (R)-3-(1-Methylcyclopropyl)-1-[(tetrahydrofuran-2-yl)methyl]-1H-pyrazol-5-amine 1140917-73-2P 1140917-81-2P
1140917-82-3P 1140917-83-4P 1140917-84-5P 1140917-85-6P
1140917-87-8P 1140917-93-6P 1140917-96-9P,
(R)-[(Tetrahydrofuran-2-yl)methyl]hydrazine dihydrochloride
1140917-97-0P 1140917-98-1P, (R)-3-tert-Butyl-1-[(tetrahydrofuran-2-yl)methyl]-1H-pyrazol-5-amine hydrochloride 1140917-99-2P
1140918-13-3P 1140918-17-7P, (R)-4-tert-Butyl-1-[(tetrahydrofuran-2-yl)methyl]pyridin-2(1H)-imine 1140918-20-2P 1140918-21-3P
1140918-22-4P, 3-tert-Butyl-1-[(tetrahydro-2H-pyran-2-yl)methyl]-1H-pyrazol-5-amine 1140918-23-5P, N-[3-tert-Butyl-1-[(tetrahydro-2H-pyran-2-yl)methyl]-1H-pyrazol-5-yl]-2-methoxy-5-(trifluoromethyl)benzamide
1140918-25-7P 1140918-26-8P 1140918-27-9P 1140918-28-0P
1140918-29-1P 1140918-31-5P 1140918-32-6P 1140918-33-7P
1140918-34-8P 1140918-35-9P 1140918-37-1P, tert-Butyl (5-tert-butyl-1,3,4-thiadiazol-2-yl)carbamate 1140918-38-2P
1140918-39-3P, (R)-5-tert-Butyl-3-[(tetrahydrofuran-2-yl)methyl]-1,3,4-thiadiazol-2(3H)-imine 1140918-62-2P 1140918-63-3P,
3-tert-Butyl-1-[(tetrahydrofuran-3-yl)methyl]-N-trityl-1H-pyrazol-5-amine
1140918-64-4P, 3-tert-Butyl-1-[(tetrahydrofuran-3-yl)methyl]-1H-pyrazol-5-amine 1140918-65-5P, N-[3-tert-Butyl-1-[(tetrahydrofuran-3-yl)methyl]-1H-pyrazol-5-yl]-2-methoxy-5-(trifluoromethyl)benzamide 1140918-76-8P
1140918-77-9P 1140918-80-4P, (S)-2-[(1-Methylpyrrolidin-3-yl)oxy]-5-(trifluoromethyl)benzonitrile 1140918-81-5P,
(S)-2-[(1-Methylpyrrolidin-3-yl)oxy]-5-(trifluoromethyl)benzoic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic
compds. as therapeutic cannabinoid receptor ligands)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l2
L7 5 L2

=> d sca

L7 5 ANSWERS ZCAPLUS COPYRIGHT 2009 ACS on STN
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
TI Preparation of phenylpyrazole derivatives as P2X7 receptor antagonists
ST pyrazole cyclopentapyrazole thienopyrazole phenyl prepn P2X7 Purinoceptor antagonist
IT Nervous system, disease
(Huntington's chorea; preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)
IT Purinoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(P2x7, antagonists of; preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)
IT Pain
(inflammatory pain, chronic; preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)
IT Pain
(neuropathic pain; preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)
IT Alzheimer's disease
Amyotrophic lateral sclerosis
Analgesics
Anti-Alzheimer's agents

Anti-inflammatory agents
Antidepressants
Antiparkinsonian agents
Antirheumatic agents
Central nervous system, disease
Depression
Human
Inflammation
Lewy body dementia
Multiple sclerosis
Neurodegenerative disease
Pain
Parkinson's disease
Rheumatoid arthritis
(preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)

IT Brain disease
(trauma; preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)

IT 936840-72-1P, N-[2-(2,3-Dichlorophenyl)-2H-pyrazol-3-yl]-2-methylbenzamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)

IT 936840-74-3P, [2-(2,3-Dichlorophenyl)-2H-pyrazol-3-yl](2-methylbenzyl)amine 936840-75-4P, [2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl][(pyridin-3-yl)methyl]amine 936840-78-7P, [2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl](2-methylbenzyl)amine 936840-79-8P, [2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl][(2-methylpyridin-3-yl)methyl]amine 936840-81-2P, [2-(2,3-Dichlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl][(2-methylpyridin-3-yl)methyl]amine 936840-84-5P, 5-Benzylamino-1-(2,3-dichlorophenyl)-1H-pyrazole-4-carbonitrile 936840-86-7P, [2-(2,3-Dichlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl](2-methylbenzyl)amine 936840-88-9P, 1-(2,3-Dichlorophenyl)-5-[[(pyridin-3-yl)methyl]amino]-1H-pyrazole-4-carbonitrile 936840-89-0P, [2-(2,3-Dichlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl][(2-methylpyridin-3-yl)methyl]amine 936840-92-5P, 1-(2,3-Dichlorophenyl)-5-[[(2-methylpyridin-3-yl)methyl]amino]-1H-pyrazole-4-carbonitrile 936840-93-6P, [2-(2,3-Dichlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl][(2-phenoxypyridin-3-yl)methyl]amine 936840-95-8P, [2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl][(2-phenoxypyridin-3-yl)methyl]amine 936840-97-0P, [2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl](2-phenoxybenzyl)amine 936840-99-2P, [[2-(3-Chlorophenoxy)pyridin-3-yl]methyl][2-(2,3-dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)

IT 100-46-9, Benzylamine, reactions 123-06-8 933-88-0, 2-Methylbenzoyl chloride 2243-42-7, 2-Phenoxybenzoic acid 2941-29-9, 2-Oxocyclopentanecarbonitrile 3222-56-8, 2-Methylnicotinic acid 3731-52-0, [(Pyridin-3-yl)methyl]amine 4513-77-3, 2-Oxocyclohexanecarbonitrile 10400-19-8, Nicotinoyl chloride 16563-14-7, 4-Oxotetrahydrothiophene-3-carbonitrile 21938-47-6, (2,3-Dichlorophenyl)hydrazine hydrochloride 35620-71-4, 2-Phenoxynicotinic acid 54629-11-7 58539-64-3, [(2-Methylpyridin-3-yl)methyl]amine
RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)
IT 73594-95-3P, 5-Amino-1-(2,3-dichlorophenyl)-1H-pyrazole-4-carbonitrile
936840-73-2P, [2-(2,3-Dichlorophenyl)-2H-pyrazol-3-yl]amine
936840-76-5P, 2-(2,3-Dichlorophenyl)-2,4,5,6-
tetrahydrocyclopenta[c]pyrazol-3-amine 936840-77-6P,
N-[2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-
yl]nicotinamide 936840-80-1P,
N-[2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-2-
methylnicotinamide 936840-82-3P,
[2-(2,3-Dichlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]amine
936840-83-4P, N-[2-(2,3-Dichlorophenyl)-2,6-dihydro-4H-thieno[3,4-
c]pyrazol-3-yl]-2-methylnicotinamide 936840-85-6P,
5-Bromo-1-(2,3-dichlorophenyl)-1H-pyrazole-4-carbonitrile 936840-87-8P,
N-[2-(2,3-Dichlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-2-
methylbenzamide 936840-90-3P, [2-(2,3-Dichlorophenyl)-4,5,6,7-tetrahydro-
2H-indazol-3-yl]amine 936840-91-4P,
N-[2-(2,3-Dichlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-2-
methylnicotinamide 936840-94-7P,
N-[2-(2,3-Dichlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-2-
phenoxynicotinamide 936840-96-9P,
N-[2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-2-
phenoxynicotinamide 936840-98-1P,
N-[2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-2-
phenoxybenzamide 936841-00-8P,
2-(3-Chlorophenoxy)-N-[2-(2,3-dichlorophenyl)-2,4,5,6-
tetrahydrocyclopenta[c]pyrazol-3-yl]nicotinamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L7 5 ANSWERS ZCAPLUS COPYRIGHT 2009 ACS on STN
INCL 514336000; 548136000; 546283400; 548240000; 548365700; 548215000;
514374000; 514378000; 514406000; 514363000
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
TI Preparation of pyrazoles, oxazoles, and other nitrogen-containing
heterocyclic compounds as therapeutic cannabinoid receptor ligands
ST nitrogen contg heterocycle prepn therapeutic cannabinoid receptor ligand;
pain treatment nitrogen contg heterocycle cannabinoid receptor ligand
IT Immune disease
(cancer of immune system; preparation of pyrazoles, oxazoles, and other
nitrogen-containing heterocyclic compds. as therapeutic cannabinoid
receptor ligands)
IT Pain
(inflammatory pain; preparation of pyrazoles, oxazoles, and other
nitrogen-containing heterocyclic compds. as therapeutic cannabinoid
receptor ligands)
IT Pain
(neuropathic pain; preparation of pyrazoles, oxazoles, and other
nitrogen-containing heterocyclic compds. as therapeutic cannabinoid
receptor ligands)
IT Analgesics
Anti-inflammatory agents
Antidiabetic agents
Antiobesity agents
Antitumor agents
Cardiovascular agents
Cardiovascular disease
Diabetes mellitus
Drug delivery systems

Human
Immune disease
Immunomodulators
Inflammation
Nervous system, disease
Nervous system agents
Neuroprotective agents
Obesity
Pain
Prophylaxis
Respiratory system agents
Respiratory system disease
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic
compds. as therapeutic cannabinoid receptor ligands)

IT Cannabinoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type CB2; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)

IT 371-62-0P, 2-Fluoroethanol 1140917-43-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)

IT 1140917-13-0P 1140917-16-3P 1140917-18-5P 1140917-19-6P
1140917-20-9P 1140917-22-1P 1140917-24-3P 1140917-27-6P
1140917-29-8P 1140917-32-3P 1140917-34-5P 1140917-37-8P
1140917-41-4P 1140917-48-1P 1140917-49-2P 1140917-53-8P
1140917-54-9P 1140917-55-0P 1140917-56-1P 1140917-57-2P
1140917-58-3P 1140917-59-4P 1140917-60-7P 1140917-61-8P
1140917-62-9P 1140917-63-0P 1140917-64-1P 1140917-65-2P
1140917-66-3P 1140917-67-4P 1140917-68-5P 1140917-71-0P
1140917-75-4P 1140917-76-5P 1140917-77-6P 1140917-78-7P
1140917-79-8P 1140917-88-9P 1140917-89-0P 1140917-90-3P
1140917-91-4P 1140917-92-5P 1140917-94-7P 1140917-95-8P
1140918-00-8P 1140918-01-9P 1140918-02-0P 1140918-03-1P
1140918-04-2P 1140918-05-3P 1140918-06-4P 1140918-07-5P
1140918-08-6P 1140918-09-7P 1140918-10-0P 1140918-11-1P
1140918-12-2P 1140918-14-4P 1140918-15-5P 1140918-16-6P
1140918-18-8P 1140918-19-9P 1140918-24-6P 1140918-30-4P
1140918-36-0P 1140918-40-6P 1140918-41-7P 1140918-42-8P
1140918-43-9P 1140918-44-0P 1140918-45-1P 1140918-46-2P
1140918-47-3P 1140918-48-4P 1140918-49-5P 1140918-50-8P
1140918-51-9P 1140918-52-0P 1140918-54-2P 1140918-57-5P
1140918-59-7P 1140918-60-0P 1140918-61-1P 1140918-66-6P
1140918-67-7P 1140918-68-8P 1140918-69-9P 1140918-70-2P
1140918-71-3P 1140918-72-4P 1140918-73-5P 1140918-74-6P
1140918-75-7P 1140918-78-0P 1140918-79-1P 1140918-82-6P
1140918-83-7P 1140918-84-8P 1140918-85-9P 1141889-94-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)

IT 401892-81-7P, 3-(Pentafluorosulfanyl)benzoyl chloride 1140917-17-4P
1140917-33-4P 1140917-39-0P 1140917-47-0P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic

compds. as therapeutic cannabinoid receptor ligands)

IT 57-57-8, 2-Oxetanone 75-64-9, 2-Methylpropan-2-amine, reactions 75-89-8, 2,2,2-Trifluoroethanol 76-83-5 79-19-6, Thiosemicarbazide 98-59-9, 4-Methylbenzene-1-sulfonyl chloride 104-75-6, 2-Ethylhexan-1-amine 108-01-0, 2-(Dimethylamino)ethanol 109-85-3, 2-Methoxyethanamine 110-18-9, N,N,N',N'-Tetramethylethane-1,2-diamine 110-52-1, 1,4-Dibromobutane 110-80-5, 2-Ethoxyethanol 111-35-3, 3-Ethoxypropan-1-ol 124-68-5, 2-Amino-2-methylpropan-1-ol 134-11-2, 2-Ethoxybenzoic acid 359-13-7, 2,2-Difluoroethanol 406-34-8, 2-Fluoroethanamine 407-25-0, 2,2,2-Trifluoroacetic anhydride 430-50-2, 1-Fluoropropan-2-ol 533-67-5, (3S,4R)-3,4,5-Trihydroxypentanal 556-82-1, 3-Methylbut-2-en-1-ol 598-74-3, 3-Methylbutan-2-amine 616-24-0, 3-Pentanamine 657-05-6, 2-Chloro-5-(trifluoromethyl)benzoyl chloride 833-96-5, 3-(Pentafluorothio)benzoic acid 1120-56-5, Methylenecyclobutane 1192-30-9, 2-(Bromomethyl)tetrahydrofuran 1589-49-7, 3-Methoxypropan-1-ol 1603-41-4, 5-Methylpyridin-2-amine 2026-48-4, (S)-2-Amino-3-methylbutan-1-ol 2217-40-5, 1,2,3,4-Tetrahydronaphthalen-1-amine 2568-33-4, 3-Methylbutane-1,3-diol 2941-29-9, 2-Oxocyclopentanecarbonitrile 3433-90-7, 2-Methoxy-5-cyanobenzoyl chloride 3438-16-2, 5-Chloro-2-methoxybenzoic acid 3824-87-1, 2-Fluoropropan-1-ol 4088-84-0, 2-Fluoro-5-(trifluoromethyl)benzonitrile 4637-24-5 4864-01-1, 2-Methoxy-5-(trifluoromethyl)benzoic acid 5241-58-7, (S)-2-Amino-3-phenylpropanamide 5452-35-7, Cycloheptanamine 5469-26-1, 1-Bromo-3,3-dimethylbutan-2-one 5813-64-9, 2,2-Dimethylpropan-1-amine 6206-25-3 6321-23-9, 4-Methylcyclohexanamine 6914-76-7, 1-Methylcyclopropane-1-carboxylic acid 7202-43-9, (R)-(Tetrahydrofuran-2-yl)methylamine 7533-40-6, (S)-2-Amino-4-methylpentan-1-ol 7547-97-9 14445-54-6, (2S,3S)-2-Amino-3-methylpentanamide 15833-61-1, (Tetrahydrofuran-3-yl)methanol 16466-61-8 17342-08-4, (S)-5-(Hydroxymethyl)pyrrolidin-2-one 17397-24-9, (S)-Hex-5-en-2-ol 17397-29-4, (R)-Hex-5-en-2-ol 17430-98-7, (S)-1-Cyclohexylethanamine 17768-41-1, (Adamantylmethyl)amine 17869-77-1, Trimethyl(2-methyl-3-butyn-2-yloxy)silane 18162-48-6, tert-Butyldimethylsilyl chloride 21900-51-6, 2-Chloro-5-fluorobenzoyl chloride 22374-89-6, 4-Phenylbutan-2-amine 22415-59-4, ((R)-Tetrahydrofuran-2-yl)methanol 25015-63-8, 4,4,5,5-Tetramethyl-1,3,2-dioxaborolane 33252-26-5, 4-tert-Butylpyridin-2-amine 34723-82-5, 2-(Bromomethyl)tetrahydro-2H-pyran 39222-73-6, 2-Amino-5-tert-butyl-1,3,4-thiadiazole 40615-36-9 55809-36-4, 5-tert-Butylisoxazol-3-amine 56539-66-3, 3-Methoxy-3-methylbutan-1-ol 56663-76-4, 2,2-Dimethyl-3-butynoic acid 57203-01-7 57235-50-4, 5-Cyclopropyl-1,3,4-thiadiazol-2-amine 59997-51-2, 4,4-Dimethyl-3-oxopentanenitrile 62910-63-8, 2-Methoxy-5-bromobenzoyl chloride 64507-07-9, 2-Methoxy-5-(trifluoromethyl)benzoyl chloride 66673-40-3, (R)-5-(Hydroxymethyl)pyrrolidin-2-one 73522-42-6, ((1S,2R,5S)-6,6-Dimethylbicyclo[3.1.1]heptan-2-yl)methanamine 82560-12-1, 3-tert-Butyl-2H-pyrazol-5-amine 83306-84-7, (R)-Tetrahydrofuran-2-ol 89226-12-0, (S)-2-Amino-N-methyl-3,3-dimethylbutanamide 104641-59-0, (S)-1-Methylpyrrolidin-3-ol 107496-54-8, 3,3-Difluorocyclobutanecarboxylic acid 108551-60-6, 5-Bromo-2,3-dihydrobenzofuran-7-carbonyl chloride 111857-74-0, (S)-Tetrahydrofuran-2-ol 112245-13-3, (S)-2-Amino-3,3-dimethylbutan-1-ol 115029-23-7, 2-Fluoro-5-(trifluoromethyl)benzoic acid 116422-39-0, (S)-2-Methoxypropan-1-ol 141699-55-0, tert-Butyl 3-hydroxyazetidine-1-carboxylate 154669-49-5, 4-Methylbenzenesulfonic acid (S)-(2-oxo-1,3-oxazolidin-4-yl)methyl ester 165059-42-7, (E)-2-(3-Methoxyprop-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 171243-30-4, 3-Fluoro-5-trifluoromethylbenzoyl chloride 172324-68-4

183616-18-4, 3-(Hydroxymethyl)cyclobutanone 207981-46-2,
2-Fluoro-5-(trifluoromethyl)benzoyl chloride 208173-19-7,
2-Fluoro-3-(trifluoromethyl)benzoyl chloride 240800-48-0,
2,3,5-Trifluorobenzoyl chloride 261763-03-5,
3-Chloro-2-fluoro-5-(trifluoromethyl)benzoyl chloride 261952-08-3,
2-Methyl-5-(trifluoromethyl)benzoyl chloride 277756-45-3,
1-(Trifluoromethyl)cyclobutanecarboxylic acid 277756-46-4,
1-(Trifluoromethyl)cyclopropanecarboxylic acid 472809-65-7,
2-Ethoxy-5-(trifluoromethyl)benzoic acid 773140-42-4 876747-18-1,
(R)-2-Fluoropropan-1-ol 889940-13-0,
3,3,3-Trifluoro-2,2-dimethylpropanoic acid 895157-70-7,
2,2,3,3-Tetrafluoro-1-methylcyclobutanecarbonyl chloride 944836-48-0,
2-Bromo-5-trifluoromethylbenzoyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic
compds. as therapeutic cannabinoid receptor ligands)

IT 6970-72-5P, 1-(Hydroxymethyl)cyclobutanol 13942-76-2P,
(2R,3S)-Pentane-1,2,3,5-tetraol 15833-63-3P,
(Tetrahydrofuran-3-yl)methyl 4-methylbenzenesulfonate 22415-60-7P,
4-Methylbenzenesulfonic acid (2R)-tetrahydrofuran-2-ylmethyl ester
29568-33-0P, 5-Chloro-2-methoxybenzoyl chloride 73089-93-7P,
1-(2-Hydroxyethyl)cyclopentanol 88485-78-3P,
3-(1-Methylcyclopropyl)-3-oxopropanenitrile 91547-59-0P,
(2R,3S)-2-(Hydroxymethyl)tetrahydrofuran-3-ol 95049-01-7P,
(2R,3S)-2-[[Bis(4-methoxyphenyl)(phenyl)methoxy]methyl]tetrahydrofuran-3-ol 97987-64-9P, 5-(1,1-Dimethylprop-2-ynyl)-1,3,4-thiadiazol-2-amine
114114-90-8P, 4-Methylbenzenesulfonic acid (2S)-tetrahydrofuran-2-ylmethyl ester 432509-85-8P, N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-5-chloro-2-methoxybenzamide 681128-39-2P 908269-41-0P,
5-(1-Methylcyclopropyl)-1,3,4-thiadiazol-2-amine 959600-77-2P,
[[(cis-3-Methoxycyclobutyl)methoxy]methyl]benzene 959600-78-3P,
(cis-3-Methoxycyclobutyl)methanol 959749-92-9P,
[[cis-3-[(Benzyloxy)methyl]cyclobutyl]oxy](tert-butyl)dimethylsilane
959749-93-0P, [cis-3-[(tert-Butyldimethylsilyl)oxy]cyclobutyl]methanol
1032464-60-0P, 5-[1-(Trifluoromethyl)cyclobutyl]-1,3,4-thiadiazol-2-amine
1034356-15-4P, (R)-Tetrahydrofuran-2-ylmethylcyanamide 1138162-60-3P
1140917-14-1P 1140917-15-2P 1140917-21-0P 1140917-23-2P
1140917-25-4P 1140917-26-5P 1140917-28-7P 1140917-30-1P
1140917-31-2P 1140917-36-7P 1140917-38-9P 1140917-40-3P
1140917-42-5P 1140917-44-7P 1140917-45-8P 1140917-46-9P
1140917-50-5P 1140917-51-6P 1140917-52-7P 1140917-69-6P
1140917-70-9P 1140917-72-1P 1140917-73-2P 1140917-81-2P
1140917-82-3P 1140917-83-4P 1140917-84-5P 1140917-85-6P
1140917-87-8P 1140917-93-6P 1140917-96-9P 1140917-97-0P
1140917-98-1P 1140917-99-2P 1140918-13-3P 1140918-17-7P
1140918-20-2P 1140918-21-3P 1140918-22-4P 1140918-23-5P
1140918-25-7P 1140918-26-8P 1140918-27-9P 1140918-28-0P
1140918-29-1P 1140918-31-5P 1140918-32-6P 1140918-33-7P
1140918-34-8P 1140918-35-9P 1140918-37-1P 1140918-38-2P
1140918-39-3P 1140918-62-2P 1140918-63-3P 1140918-64-4P
1140918-65-5P 1140918-76-8P 1140918-77-9P 1140918-80-4P
1140918-81-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic
compds. as therapeutic cannabinoid receptor ligands)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L7 5 ANSWERS ZCAPLUS COPYRIGHT 2009 ACS on STN

CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
TI Reactions of isatoic anhydride with some aminoheterocycles
ST isatoic anhydride heterocyclic amine amidation; heterocycle substituted anthranilic acid amide prepn; anthranilamide heterocycle substituted deriv prepn; tetrahydroquinazolinyl quinazolinone deriv prepn
IT Amides, preparation
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(aryl, heterocyclic; preparation of heterocycle-substituted anthranilic acid amides via amidation reactions of isatoic anhydride with aminoheterocycles)
IT Amines, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(heterocyclic; preparation of heterocycle-substituted anthranilic acid amides via amidation reactions of isatoic anhydride with aminoheterocycles)
IT Amidation
(preparation of heterocycle-substituted anthranilic acid amides via amidation reactions of isatoic anhydride with aminoheterocycles)
IT 118-48-9, Isatoic anhydride 4149-06-8 4815-30-9 5805-39-0, 2-(2-Aminophenyl)benzimidazole 21599-37-1 24764-63-4 26093-31-2, 7-Amino-4-methylcoumarin 1001049-60-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocycle-substituted anthranilic acid amides via amidation reactions of isatoic anhydride with aminoheterocycles)
IT 1016638-23-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocycle-substituted anthranilic acid amides via amidation reactions of isatoic anhydride with aminoheterocycles)
IT 96057-32-8P 1016638-24-6P 1016638-25-7P 1016638-26-8P 1016638-27-9P 1016638-28-0P 1016638-29-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of heterocycle-substituted anthranilic acid amides via amidation reactions of isatoic anhydride with aminoheterocycles)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L7 5 ANSWERS ZCAPLUS COPYRIGHT 2009 ACS on STN
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
TI Preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compounds as therapeutic cannabinoid receptor ligands
ST nitrogen contg heterocycle prepn therapeutic cannabinoid receptor ligand; pain treatment nitrogen contg heterocycle cannabinoid receptor ligand
IT Immune disease
(cancer of immune system; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)
IT Pain
(inflammatory pain; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)
IT Pain
(neuropathic pain; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)
IT Analgesics
Anti-inflammatory agents
Antidiabetic agents
Antiobesity agents
Antitumor agents

Cardiovascular agents
Cardiovascular disease
Diabetes mellitus
Drug delivery systems
Human
Immune disease
Immunomodulators
Inflammation
Nervous system, disease
Nervous system agents
Neuroprotective agents
Obesity
Pain
Prophylaxis
Respiratory system agents
Respiratory system disease
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)

IT Cannabinoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type CB2; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)

IT 371-62-0P, 2-Fluoroethanol 1140917-43-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)

IT 1140917-13-0P 1140917-16-3P 1140917-18-5P 1140917-19-6P
1140917-20-9P 1140917-22-1P 1140917-24-3P 1140917-27-6P
1140917-29-8P 1140917-32-3P 1140917-34-5P 1140917-37-8P
1140917-41-4P 1140917-48-1P 1140917-49-2P 1140917-53-8P
1140917-54-9P 1140917-55-0P 1140917-56-1P 1140917-57-2P
1140917-58-3P 1140917-59-4P 1140917-60-7P 1140917-61-8P
1140917-62-9P 1140917-63-0P 1140917-64-1P 1140917-65-2P
1140917-66-3P 1140917-67-4P 1140917-68-5P 1140917-71-0P
1140917-75-4P 1140917-76-5P 1140917-77-6P 1140917-78-7P
1140917-79-8P 1140917-88-9P 1140917-89-0P 1140917-90-3P
1140917-91-4P 1140917-92-5P 1140917-94-7P 1140917-95-8P
1140918-00-8P 1140918-01-9P 1140918-02-0P 1140918-03-1P
1140918-04-2P 1140918-05-3P 1140918-06-4P 1140918-07-5P
1140918-08-6P 1140918-09-7P 1140918-10-0P 1140918-11-1P
1140918-12-2P 1140918-14-4P 1140918-15-5P 1140918-16-6P
1140918-18-8P 1140918-19-9P 1140918-24-6P 1140918-30-4P
1140918-36-0P 1140918-40-6P 1140918-41-7P 1140918-42-8P
1140918-43-9P 1140918-44-0P 1140918-45-1P 1140918-46-2P
1140918-47-3P 1140918-48-4P 1140918-49-5P 1140918-50-8P
1140918-51-9P 1140918-52-0P 1140918-54-2P 1140918-57-5P
1140918-59-7P 1140918-60-0P 1140918-61-1P 1140918-66-6P
1140918-67-7P 1140918-68-8P 1140918-69-9P 1140918-70-2P
1140918-71-3P 1140918-72-4P 1140918-73-5P 1140918-74-6P
1140918-75-7P 1140918-78-0P 1140918-79-1P 1140918-82-6P
1140918-83-7P 1140918-84-8P 1140918-85-9P 1141889-94-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)

IT 401892-81-7P, 3-(Pentafluorosulfanyl)benzoyl chloride 1140917-17-4P,

5-Cyclopropyl-3-[(tetrahydrofuran-2-yl)methyl]-1,3,4-thiadiazol-2(3H)-imine 1140917-33-4P, 5-Methyl-1-[(tetrahydrofuran-2-yl)methyl]pyridin-2(1H)-imine hydrobromide 1140917-39-0P 1140917-47-0P, 2-Ethoxy-5-(trifluoromethyl)benzoyl chloride
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic
compds. as therapeutic cannabinoid receptor ligands)

IT 57-57-8, 2-Oxetanone 75-64-9, 2-Methylpropan-2-amine, reactions 75-89-8, 2,2,2-Trifluoroethanol 76-83-5 79-19-6, Thiosemicarbazide 98-59-9, 4-Methylbenzene-1-sulfonyl chloride 104-75-6, 2-Ethylhexan-1-amine 108-01-0, 2-(Dimethylamino)ethanol 109-85-3, 2-Methoxyethanamine 110-18-9, N,N,N',N'-Tetramethylethane-1,2-diamine 110-52-1, 1,4-Dibromobutane 110-80-5, 2-Ethoxyethanol 111-35-3, 3-Ethoxypropan-1-ol 124-68-5, 2-Amino-2-methylpropan-1-ol 134-11-2, 2-Ethoxybenzoic acid 359-13-7, 2,2-Difluoroethanol 406-34-8, 2-Fluoroethanamine 407-25-0, 2,2,2-Trifluoroacetic anhydride 430-50-2, 1-Fluoropropan-2-ol 533-67-5, (3S,4R)-3,4,5-Trihydroxypentanal 556-82-1, 3-Methylbut-2-en-1-ol 598-74-3, 3-Methylbutan-2-amine 616-24-0, 3-Pentanamine 657-05-6, 2-Chloro-5-(trifluoromethyl)benzoyl chloride 833-96-5, 3-(Pentafluorothio)benzoic acid 1120-56-5, Methylenecyclobutane 1192-30-9, 2-(Bromomethyl)tetrahydrofuran 1589-49-7, 3-Methoxypropan-1-ol 1603-41-4, 5-Methylpyridin-2-amine 2026-48-4, (S)-2-Amino-3-methylbutan-1-ol 2217-40-5, 1,2,3,4-Tetrahydronaphthalen-1-amine 2568-33-4, 3-Methylbutane-1,3-diol 2941-29-9, 2-Oxocyclopentanecarbonitrile 3433-90-7, 2-Methoxy-5-cyanobenzoyl chloride 3438-16-2, 5-Chloro-2-methoxybenzoic acid 3824-87-1, 2-Fluoropropan-1-ol 4088-84-0, 2-Fluoro-5-(trifluoromethyl)benzonitrile 4637-24-5 4864-01-1, 2-Methoxy-5-(trifluoromethyl)benzoic acid 5241-58-7, (S)-2-Amino-3-phenylpropanamide 5452-35-7, Cycloheptanamine 5469-26-1, 1-Bromo-3,3-dimethylbutan-2-one 5813-64-9, 2,2-Dimethylpropan-1-amine 6206-25-3 6321-23-9, 4-Methylcyclohexanamine 6914-76-7, 1-Methylcyclopropane-1-carboxylic acid 7202-43-9, (R)-(Tetrahydrofuran-2-yl)methylamine 7533-40-6, (S)-2-Amino-4-methylpentan-1-ol 7547-97-9 14445-54-6, (2S,3S)-2-Amino-3-methylpentanamide 15833-61-1, (Tetrahydrofuran-3-yl)methanol 16466-61-8 17342-08-4, (S)-5-(Hydroxymethyl)pyrrolidin-2-one 17397-24-9, (S)-Hex-5-en-2-ol 17397-29-4, (R)-Hex-5-en-2-ol 17430-98-7, (S)-1-Cyclohexylethanamine 17768-41-1, (Adamantylmethyl)amine 17869-77-1, Trimethyl(2-methyl-3-butyn-2-yloxy)silane 18162-48-6, tert-Butyldimethylsilyl chloride 21900-51-6, 2-Chloro-5-fluorobenzoyl chloride 22374-89-6, 4-Phenylbutan-2-amine 22415-59-4, ((R)-Tetrahydrofuran-2-yl)methanol 25015-63-8, 4,4,5,5-Tetramethyl-1,3,2-dioxaborolane 33252-26-5, 4-tert-Butylpyridin-2-amine 34723-82-5, 2-(Bromomethyl)tetrahydro-2H-pyran 39222-73-6, 2-Amino-5-tert-butyl-1,3,4-thiadiazole 40615-36-9 55809-36-4, 5-tert-Butylisoxazol-3-amine 56539-66-3, 3-Methoxy-3-methylbutan-1-ol 56663-76-4, 2,2-Dimethyl-3-butynoic acid 57203-01-7 57235-50-4, 5-Cyclopropyl-1,3,4-thiadiazol-2-amine 59997-51-2, 4,4-Dimethyl-3-oxopentanenitrile 62910-63-8, 2-Methoxy-5-bromobenzoyl chloride 64507-07-9, 2-Methoxy-5-(trifluoromethyl)benzoyl chloride 66673-40-3, (R)-5-(Hydroxymethyl)pyrrolidin-2-one 73522-42-6, ((1S,2R,5S)-6,6-Dimethylbicyclo[3.1.1]heptan-2-yl)methanamine 82560-12-1, 3-tert-Butyl-2H-pyrazol-5-amine 83306-84-7, (R)-Tetrahydrofuran-2-ol 89226-12-0, (S)-2-Amino-N-methyl-3,3-dimethylbutanamide 104641-59-0, (S)-1-Methylpyrrolidin-3-ol 107496-54-8, 3,3-Difluorocyclobutanecarboxylic acid 108551-60-6,

5-Bromo-2,3-dihydrobenzofuran-7-carbonyl chloride 111857-74-0, (S)-Tetrahydrofuran-2-ol 112245-13-3, (S)-2-Amino-3,3-dimethylbutan-1-ol 115029-23-7, 2-Fluoro-5-(trifluoromethyl)benzoic acid 116422-39-0, (S)-2-Methoxypropan-1-ol 141699-55-0, tert-Butyl 3-hydroxyazetidine-1-carboxylate 154669-49-5, 4-Methylbenzenesulfonic acid (S)-(2-oxo-1,3-oxazolidin-4-yl)methyl ester 165059-42-7, (E)-2-(3-Methoxyprop-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 171243-30-4, 3-Fluoro-5-trifluoromethylbenzoyl chloride 172324-68-4 183616-18-4, 3-(Hydroxymethyl)cyclobutanone 207981-46-2, 2-Fluoro-5-(trifluoromethyl)benzoyl chloride 208173-19-7, 2-Fluoro-3-(trifluoromethyl)benzoyl chloride 240800-48-0, 2,3,5-Trifluorobenzoyl chloride 261763-03-5, 3-Chloro-2-fluoro-5-(trifluoromethyl)benzoyl chloride 261952-08-3, 2-Methyl-5-(trifluoromethyl)benzoyl chloride 277756-45-3, 1-(Trifluoromethyl)cyclobutanecarboxylic acid 277756-46-4, 1-(Trifluoromethyl)cyclopropanecarboxylic acid 472809-65-7, 2-Ethoxy-5-(trifluoromethyl)benzoic acid 773140-42-4 876747-18-1, (R)-2-Fluoropropan-1-ol 889940-13-0, 3,3,3-Trifluoro-2,2-dimethylpropanoic acid 895157-70-7, 2,2,3,3-Tetrafluoro-1-methylcyclobutanecarbonyl chloride 944836-48-0, 2-Bromo-5-trifluoromethylbenzoyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic
compds. as therapeutic cannabinoid receptor ligands)

IT 6970-72-5P, 1-(Hydroxymethyl)cyclobutanol 13942-76-2P, (2R,3S)-Pentane-1,2,3,5-tetraol 15833-63-3P, (Tetrahydrofuran-3-yl)methyl 4-methylbenzenesulfonate 22415-60-7P, 4-Methylbenzenesulfonic acid (2R)-tetrahydrofuran-2-ylmethyl ester 29568-33-0P, 5-Chloro-2-methoxybenzoyl chloride 73089-93-7P, 1-(2-Hydroxyethyl)cyclopentanol 88485-78-3P, 3-(1-Methylcyclopropyl)-3-oxopropanenitrile 91547-59-0P, (2R,3S)-2-(Hydroxymethyl)tetrahydrofuran-3-ol 95049-01-7P, (2R,3S)-2-[[Bis(4-methoxyphenyl)(phenyl)methoxy]methyl]tetrahydrofuran-3-ol 97987-64-9P, 5-(1,1-Dimethylprop-2-ynyl)-1,3,4-thiadiazol-2-amine 114114-90-8P, 4-Methylbenzenesulfonic acid (2S)-tetrahydrofuran-2-ylmethyl ester 432509-85-8P, N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-5-chloro-2-methoxybenzamide 681128-39-2P 908269-41-0P, 5-(1-Methylcyclopropyl)-1,3,4-thiadiazol-2-amine 959600-77-2P, [[(cis-3-Methoxycyclobutyl)methoxy]methyl]benzene 959600-78-3P, (cis-3-Methoxycyclobutyl)methanol 959749-92-9P, [[cis-3-[(Benzyloxy)methyl]cyclobutyl]oxy](tert-butyl)dimethylsilane 959749-93-0P, [cis-3-[(tert-Butyldimethylsilyl)oxy]cyclobutyl]methanol 1032464-60-0P, 5-[1-(Trifluoromethyl)cyclobutyl]-1,3,4-thiadiazol-2-amine 1034356-15-4P, (R)-Tetrahydrofuran-2-ylmethylcyanamide 1138162-60-3P 1140917-14-1P, 5-[1-(Trifluoromethyl)cyclopropyl]-1,3,4-thiadiazol-2-amine 1140917-15-2P 1140917-21-0P, 5-Chloro-2-methoxy-N-[5-(1-methylcyclopropyl)-1,3,4-thiadiazol-2-yl]benzamide 1140917-23-2P, 5-Chloro-N-[5-(1,1-dimethylprop-2-ynyl)-1,3,4-thiadiazol-2-yl]-2-methoxybenzamide 1140917-25-4P, 5-(2,2,3,3-Tetrafluoro-1-methylcyclobutyl)-1,3,4-thiadiazol-2-amine 1140917-26-5P, 5-Chloro-2-methoxy-N-[5-(2,2,3,3-tetrafluoro-1-methylcyclobutyl)-1,3,4-thiadiazol-2-yl]benzamide 1140917-28-7P 1140917-30-1P, 5-(2,2,2-Trifluoro-1,1-dimethylethyl)-1,3,4-thiadiazol-2-amine 1140917-31-2P 1140917-36-7P 1140917-38-9P 1140917-40-3P 1140917-42-5P, (R)-5-tert-Butyl-3-[(tetrahydrofuran-2-yl)methyl]oxazol-2(3H)-imine 1140917-44-7P, (R)-N-[3-tert-Butyl-1-[(tetrahydrofuran-2-yl)methyl]-1H-pyrazol-5-yl]-2,2,2-trifluoroethanamide 1140917-45-8P 1140917-46-9P 1140917-50-5P 1140917-51-6P 1140917-52-7P 1140917-69-6P, (S)-2-[(Tetrahydrofuran-2-yl)methyl]-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-amine 1140917-70-9P 1140917-72-1P, (R)-3-(1-Methylcyclopropyl)-1-[(tetrahydrofuran-2-

yl)methyl]-1H-pyrazol-5-amine 1140917-73-2P 1140917-81-2P
1140917-82-3P 1140917-83-4P 1140917-84-5P 1140917-85-6P
1140917-87-8P 1140917-93-6P 1140917-96-9P,
(R)-[(Tetrahydrofuran-2-yl)methyl]hydrazine dihydrochloride
1140917-97-0P 1140917-98-1P, (R)-3-tert-Butyl-1-[(tetrahydrofuran-2-
yl)methyl]-1H-pyrazol-5-amine hydrochloride 1140917-99-2P
1140918-13-3P 1140918-17-7P, (R)-4-tert-Butyl-1-[(tetrahydrofuran-2-
yl)methyl]pyridin-2(1H)-imine 1140918-20-2P 1140918-21-3P
1140918-22-4P, 3-tert-Butyl-1-[(tetrahydro-2H-pyran-2-yl)methyl]-1H-
pyrazol-5-amine 1140918-23-5P, N-[3-tert-Butyl-1-[(tetrahydro-2H-pyran-2-
yl)methyl]-1H-pyrazol-5-yl]-2-methoxy-5-(trifluoromethyl)benzamide
1140918-25-7P 1140918-26-8P 1140918-27-9P 1140918-28-0P
1140918-29-1P 1140918-31-5P 1140918-32-6P 1140918-33-7P
1140918-34-8P 1140918-35-9P 1140918-37-1P, tert-Butyl
(5-tert-butyl-1,3,4-thiadiazol-2-yl)carbamate 1140918-38-2P
1140918-39-3P, (R)-5-tert-Butyl-3-[(tetrahydrofuran-2-yl)methyl]-1,3,4-
thiadiazol-2(3H)-imine 1140918-62-2P 1140918-63-3P,
3-tert-Butyl-1-[(tetrahydrofuran-3-yl)methyl]-N-trityl-1H-pyrazol-5-amine
1140918-64-4P, 3-tert-Butyl-1-[(tetrahydrofuran-3-yl)methyl]-1H-pyrazol-5-
amine 1140918-65-5P, N-[3-tert-Butyl-1-[(tetrahydrofuran-3-yl)methyl]-1H-
pyrazol-5-yl]-2-methoxy-5-(trifluoromethyl)benzamide 1140918-76-8P
1140918-77-9P 1140918-80-4P, (S)-2-[(1-Methylpyrrolidin-3-yl)oxy]-5-
(trifluoromethyl)benzonitrile 1140918-81-5P,
(S)-2-[(1-Methylpyrrolidin-3-yl)oxy]-5-(trifluoromethyl)benzoic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of pyrazoles, oxazoles, and other nitrogen-containing
heterocyclic
compds. as therapeutic cannabinoid receptor ligands)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L7 5 ANSWERS ZCAPLUS COPYRIGHT 2009 ACS on STN
IC ICM A61K031-415
ICS A61K031-416; A61K031-4162; A61K031-4164; A61K031-4155; A61K031-417;
A61K031-4172; A61K031-4184; A61K045-00; A61P001-04; A61P009-06;
A61P009-12; A61P011-02; A61P011-06; A61P013-00; A61P015-00;
A61P015-10; A61P015-12; A61P025-08; A61P025-16
CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
TI Preparation of pyrazole, fused pyrazole, and imidazole derivatives as
preventives and/or therapeutic agents for disease in which mitochondrial
benzodiazepine receptor participates
ST pyrazole prepn prevention treatment stress related disease; fused pyrazole
prepn prevention treatment stress related disease; imidazole prepn
prevention treatment stress related disease; mitochondrial benzodiazepine
receptor affinity pyrazole imidazole prepn; central nervous system disease
prevention treatment pyrazole imidazole prepn; respiratory disease
prevention treatment pyrazole imidazole prepn; digestive tract disease
prevention treatment pyrazole imidazole prepn
IT Anxiety
Asthma
Central nervous system, disease
Digestive tract, disease
Epilepsy
Nervous system agents
Respiratory system, disease
Sleep disorders
(attributable to stress; preparation of pyrazole, fused pyrazole, and
imidazole derivs. as preventive and/or therapeutic agents for disease
mediated by mitochondrial benzodiazepine receptor)
IT Mental and behavioral disorders

(depression, attributable to stress; preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

IT Intestine, disease
(irritable bowel syndrome, attributable to stress; preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

IT Benzodiazepine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(peripheral-type; preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

IT Antiasthmatics
Anticonvulsants
Antidepressants
Anxiolytics
Stress, animal
(preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

IT 110937-65-0P, Ethyl 3-(2-phenyl-1H-imidazol-4-yl)propanoate
285984-25-0P, 1-(4-Methylphenyl)-3-tert-butylpyrazole-5-amine
805961-39-1P, 3-(2-Phenyl-1H-imidazol-4-yl)propanoic acid 858668-71-0P, Ethyl (2E)-3-(1-benzyl-2-phenyl-1H-imidazol-4-yl)-2-propenoate
858668-72-1P, 3-(2-Phenyl-1H-imidazol-4-yl)propanamide 858668-93-6P, N-[2-(4-Chlorophenyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2-(4-fluorophenyl)acetamide hydrochloride
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

IT 63419-60-3P, 2-(4-Chlorophenyl)-4,5,6,7-tetrahydro-2H-indazole-3-amine
214542-52-6P, 2-(4-Chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazole-3-amine 214542-59-3P, 2-tert-Butyl-2,6-dihydro-4H-thieno[3,4-c]pyrazole-3-amine 392252-90-3P, N-(2-tert-Butyl-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl)benzamide 392253-06-4P, N-[2-(4-Chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-2-phenylacetamide 396724-30-4P, N-[2-(4-Methylphenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-2-phenylacetamide 476459-17-3P, N-[2-(4-Chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-3-phenylpropanamide 476459-32-2P, N-(2-tert-Butyl-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl)-2-(4-fluorophenyl)acetamide 521268-89-3P, 3-(2-Phenyl-1H-imidazol-4-yl)-1-propanamine 664966-72-7P, 1-tert-Butyl-4-phenyl-1H-pyrazole-5-amine 848144-06-9P, N-[3-tert-Butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]benzamide
858668-62-9P, 2-(4-Methylphenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazole-3-amine 858668-65-2P, 2-(4-Chlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-amine 858668-66-3P, 2-tert-Butyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-amine
858668-67-4P, 2-(4-Chlorophenyl)-2,4,5,6,7,8-hexahydrocyclohepta[c]pyrazole-3-amine 858668-68-5P, 3-Amino-2-(4-chlorophenyl)-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazole-5-carboxylic acid tert-butyl ester 858668-69-6P, 2-Phenyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole-3-amine 858668-73-2P, N-[3-tert-Butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-(4-fluorophenyl)acetamide 858668-74-3P, N-[3-tert-Butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-thiophenecarboxamide
858668-75-4P, N-[1-tert-Butyl-4-phenyl-1H-pyrazol-5-yl]-2-(4-fluorophenyl)acetamide 858668-76-5P, N-[1-tert-Butyl-4-phenyl-1H-pyrazol-5-yl]-3-phenylpropanamide

858668-77-6P, N-[3-(2-Phenyl-1H-imidazol-4-yl)propyl]benzamide
858668-78-7P, 2,5-Dichloro-N-[3-(2-phenyl-1H-imidazol-4-
yl)propyl]benzamide 858668-79-8P,
N-[2-(4-Chlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-2-(4-
fluorophenyl)acetamide 858668-80-1P,
N-[2-(4-Chlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-2-
phenylacetamide 858668-81-2P, N-(2-tert-Butyl-2,4,5,6-
tetrahydrocyclopenta[c]pyrazol-3-yl)-2-phenylacetamide
858668-82-3P, N-[2-(4-Chlorophenyl)-2,4,5,6,7,8-
hexahydrocyclohepta[c]pyrazol-3-yl]-2-phenylacetamide 858668-83-4P,
2-(4-Chlorophenyl)-3-[[(4-fluorophenyl)acetyl]amino]-2,6-dihydro-4H-
pyrrolo[3,4-c]pyrazole-5-carboxylic acid tert-butyl ester 858668-84-5P,
N-Phenyl-3-(2-phenyl-1H-imidazol-4-yl)propanamide 858668-85-6P,
N-(3,5-Dimethylphenyl)-3-(2-phenyl-1H-imidazol-4-yl)propanamide
858668-86-7P, N-[2-(4-Chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-
yl]benzenesulfonamide 858668-87-8P,
N-(2-tert-Butyl-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-
yl)benzenesulfonamide 858668-88-9P,
N-[2-(4-Chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-1-
phenylmethanesulfonamide 858668-89-0P,
N-[2-(4-Chlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-1-
phenylmethanesulfonamide 858668-90-3P,
N-[2-(4-Chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-N-
(phenylsulfonyl)benzenesulfonamide 858668-91-4P,
2-Phenyl-N-(2-phenyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)acetamide
858668-92-5P, 2-(4-Fluorophenyl)-N-(2-phenyl-6,7-dihydro-5H-pyrrolo[1,2-
a]imidazol-3-yl)acetamide 858668-94-7P,
N-[2-(4-Chlorophenyl)-5-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-
yl]-2-(4-fluorophenyl)acetamide 858668-95-8P,
1-Phenyl-N-(2-phenyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-
yl)methanesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of pyrazole, fused pyrazole, and imidazole derivs. as
preventive and/or therapeutic agents for disease mediated by
mitochondrial benzodiazepine receptor)

IT 50-00-0, Formaldehyde, reactions 62-53-3, Aniline, reactions 98-09-9,
Benzenesulfonyl chloride 98-88-4, Benzoyl chloride 100-39-0, Benzyl
bromide 103-80-0, Phenylacetyl chloride 108-69-0, 3,5-Dimethylaniline
459-04-1, (4-Fluorophenyl)acetyl chloride 539-44-6,
4-Methylphenylhydrazine 616-45-5, 2-Pyrrolidinone 867-13-0, Ethyl
(diethoxyphosphoryl)acetate 1073-69-4, 4-Chlorophenylhydrazine
1939-99-7, Benzylsulfonyl chloride 4513-77-3,
2-Oxocyclohexane-1-carbonitrile 5841-70-3, 3-Oxo-2-phenylpropanenitrile
16563-14-7, 4-Oxotetrahydrothiophene-3-carbonitrile 32064-67-8,
tert-Butylhydrazine 53641-60-4, 2-Amino-2-phenylacetonitrile
hydrochloride 59997-51-2, 4,4-Dimethyl-3-oxopentanenitrile 68282-47-3,
4-Formyl-2-phenylimidazole 80501-45-7,
2-Aminocyclopentane-1-carbonitrile 175463-32-8,
1-tert-Butoxycarbonyl-4-oxopyrrolidine-3-carbonitrile 858668-96-9,
2-Aminocyclobutane-1-carbonitrile 858668-98-1,
3-(2-Phenyl-1H-imidazol-4-yl)propanoyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazole, fused pyrazole, and imidazole derivs. as
preventive and/or therapeutic agents for disease mediated by
mitochondrial benzodiazepine receptor)

IT 99280-85-0P, 1-Benzyl-4-formyl-2-phenylimidazole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of pyrazole, fused pyrazole, and imidazole derivs. as
preventive and/or therapeutic agents for disease mediated by

mitochondrial benzodiazepine receptor)

ALL ANSWERS HAVE BEEN SCANNED

=> d s ca l6 1-5
'S' IS NOT A VALID FORMAT FOR FILE 'ZCAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes. For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO. You may specify the format fields in any order and the

information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):bib
THE ESTIMATED COST FOR THIS REQUEST IS 6.25 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:n
REQUEST CANCELED

=> d sca l6

L6 5 ANSWERS ZCAPLUS COPYRIGHT 2009 ACS on STN
IC ICM A61K031-415
    ICS A61K031-416; A61K031-4162; A61K031-4164; A61K031-4155; A61K031-417;
         A61K031-4172; A61K031-4184; A61K045-00; A61P001-04; A61P009-06;
         A61P009-12; A61P011-02; A61P011-06; A61P013-00; A61P015-00;
         A61P015-10; A61P015-12; A61P025-08; A61P025-16
CC 28-9 (Heterocyclic Compounds (More Than One Hetero Atom))
    Section cross-reference(s): 1, 63
TI Preparation of pyrazole, fused pyrazole, and imidazole derivatives as
    preventives and/or therapeutic agents for disease in which mitochondrial
    benzodiazepine receptor participates
ST pyrazole prepn prevention treatment stress related disease; fused pyrazole
    prepn prevention treatment stress related disease; imidazole prepn
    prevention treatment stress related disease; mitochondrial benzodiazepine
    receptor affinity pyrazole imidazole prepn; central nervous system disease
    prevention treatment pyrazole imidazole prepn; respiratory disease
    prevention treatment pyrazole imidazole prepn; digestive tract disease
    prevention treatment pyrazole imidazole prepn
IT Anxiety
    Asthma
    Central nervous system, disease
    Digestive tract, disease
    Epilepsy
    Nervous system agents
    Respiratory system, disease
    Sleep disorders
       (attributable to stress; preparation of pyrazole, fused pyrazole, and
       imidazole derivs. as preventive and/or therapeutic agents for disease
       mediated by mitochondrial benzodiazepine receptor)
IT Mental and behavioral disorders
       (depression, attributable to stress; preparation of pyrazole, fused
       pyrazole, and imidazole derivs. as preventive and/or therapeutic agents
       for disease mediated by mitochondrial benzodiazepine receptor)
IT Intestine, disease
       (irritable bowel syndrome, attributable to stress; preparation of pyrazole,
       fused pyrazole, and imidazole derivs. as preventive and/or therapeutic
       agents for disease mediated by mitochondrial benzodiazepine receptor)
IT Benzodiazepine receptors
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
       (peripheral-type; preparation of pyrazole, fused pyrazole, and imidazole
       derivs. as preventive and/or therapeutic agents for disease mediated by
       mitochondrial benzodiazepine receptor)
IT Antiasthmatics
    Anticonvulsants
    Antidepressants
    Anxiolytics
    Stress, animal
       (preparation of pyrazole, fused pyrazole, and imidazole derivs. as
       preventive and/or therapeutic agents for disease mediated by

mitochondrial benzodiazepine receptor)

IT 110937-65-0P, Ethyl 3-(2-phenyl-1H-imidazol-4-yl)propanoate
285984-25-0P, 1-(4-Methylphenyl)-3-tert-butylpyrazole-5-amine
805961-39-1P, 3-(2-Phenyl-1H-imidazol-4-yl)propanoic acid 858668-71-0P,
Ethyl (2E)-3-(1-benzyl-2-phenyl-1H-imidazol-4-yl)-2-propenoate
858668-72-1P, 3-(2-Phenyl-1H-imidazol-4-yl)propanamide 858668-93-6P,
N-[2-(4-Chlorophenyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2-(4-
fluorophenyl)acetamide hydrochloride
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazole, fused pyrazole, and imidazole derivs. as
preventive and/or therapeutic agents for disease mediated by
mitochondrial benzodiazepine receptor)

IT 63419-60-3P, 2-(4-Chlorophenyl)-4,5,6,7-tetrahydro-2H-indazole-3-amine
214542-52-6P, 2-(4-Chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazole-3-
amine 214542-59-3P, 2-tert-Butyl-2,6-dihydro-4H-thieno[3,4-c]pyrazole-3-
amine 392252-90-3P, N-(2-tert-Butyl-2,6-dihydro-4H-thieno[3,4-c]pyrazol-
3-yl)benzamide 392253-06-4P, N-[2-(4-Chlorophenyl)-2,6-dihydro-4H-
thieno[3,4-c]pyrazol-3-yl]-2-phenylacetamide 396724-30-4P,
N-[2-(4-Methylphenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-2-
phenylacetamide 476459-17-3P, N-[2-(4-Chlorophenyl)-2,6-dihydro-4H-
thieno[3,4-c]pyrazol-3-yl]-3-phenylpropanamide 476459-32-2P,
N-(2-tert-Butyl-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl)-2-(4-
fluorophenyl)acetamide 521268-89-3P,
3-(2-Phenyl-1H-imidazol-4-yl)-1-propanamine 664966-72-7P,
1-tert-Butyl-4-phenyl-1H-pyrazole-5-amine 848144-06-9P,
N-[3-tert-Butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]benzamide
858668-62-9P, 2-(4-Methylphenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazole-3-
amine 858668-65-2P, 2-(4-Chlorophenyl)-2,4,5,6-
tetrahydrocyclopenta[c]pyrazole-3-amine 858668-66-3P,
2-tert-Butyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-amine
858668-67-4P, 2-(4-Chlorophenyl)-2,4,5,6,7,8-
hexahydrocyclohepta[c]pyrazole-3-amine 858668-68-5P,
3-Amino-2-(4-chlorophenyl)-2,6-dihydro-4H-pyrrolo[3,4-c]pyrazole-5-
carboxylic acid tert-butyl ester 858668-69-6P,
2-Phenyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole-3-amine 858668-73-2P,
N-[3-tert-Butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-(4-
fluorophenyl)acetamide 858668-74-3P,
N-[3-tert-Butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-2-thiophenecarboxamide
858668-75-4P, N-[1-tert-Butyl-4-phenyl-1H-pyrazol-5-yl]-2-(4-
fluorophenyl)acetamide 858668-76-5P,
N-[1-tert-Butyl-4-phenyl-1H-pyrazol-5-yl]-3-phenylpropanamide
858668-77-6P, N-[3-(2-Phenyl-1H-imidazol-4-yl)propyl]benzamide
858668-78-7P, 2,5-Dichloro-N-[3-(2-phenyl-1H-imidazol-4-
yl)propyl]benzamide 858668-79-8P,
N-[2-(4-Chlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-2-(4-
fluorophenyl)acetamide 858668-80-1P,
N-[2-(4-Chlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-2-
phenylacetamide 858668-81-2P, N-(2-tert-Butyl-2,4,5,6-
tetrahydrocyclopenta[c]pyrazol-3-yl)-2-phenylacetamide
858668-82-3P, N-[2-(4-Chlorophenyl)-2,4,5,6,7,8-
hexahydrocyclohepta[c]pyrazol-3-yl]-2-phenylacetamide 858668-83-4P,
2-(4-Chlorophenyl)-3-[[(4-fluorophenyl)acetyl]amino]-2,6-dihydro-4H-
pyrrolo[3,4-c]pyrazole-5-carboxylic acid tert-butyl ester 858668-84-5P,
N-Phenyl-3-(2-phenyl-1H-imidazol-4-yl)propanamide 858668-85-6P,
N-(3,5-Dimethylphenyl)-3-(2-phenyl-1H-imidazol-4-yl)propanamide
858668-86-7P, N-[2-(4-Chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-
yl]benzenesulfonamide 858668-87-8P,
N-(2-tert-Butyl-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-
yl)benzenesulfonamide 858668-88-9P,
N-[2-(4-Chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-1-

phenylmethanesulfonamide 858668-89-0P, N-[2-(4-Chlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-1-phenylmethanesulfonamide 858668-90-3P, N-[2-(4-Chlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-N-(phenylsulfonyl)benzenesulfonamide 858668-91-4P, 2-Phenyl-N-(2-phenyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)acetamide 858668-92-5P, 2-(4-Fluorophenyl)-N-(2-phenyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)acetamide 858668-94-7P, N-[2-(4-Chlorophenyl)-5-methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl]-2-(4-fluorophenyl)acetamide 858668-95-8P, 1-Phenyl-N-(2-phenyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-3-yl)methanesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

IT 50-00-0, Formaldehyde, reactions 62-53-3, Aniline, reactions 98-09-9, Benzenesulfonyl chloride 98-88-4, Benzoyl chloride 100-39-0, Benzyl bromide 103-80-0, Phenylacetyl chloride 108-69-0, 3,5-Dimethylaniline 459-04-1, (4-Fluorophenyl)acetyl chloride 539-44-6, 4-Methylphenylhydrazine 616-45-5, 2-Pyrrolidinone 867-13-0, Ethyl (diethoxyphosphoryl)acetate 1073-69-4, 4-Chlorophenylhydrazine 1939-99-7, Benzylsulfonyl chloride 4513-77-3, 2-Oxocyclohexane-1-carbonitrile 5841-70-3, 3-Oxo-2-phenylpropanenitrile 16563-14-7, 4-Oxotetrahydrothiophene-3-carbonitrile 32064-67-8, tert-Butylhydrazine 53641-60-4, 2-Amino-2-phenylacetonitrile hydrochloride 59997-51-2, 4,4-Dimethyl-3-oxopentanenitrile 68282-47-3, 4-Formyl-2-phenylimidazole 80501-45-7, 2-Aminocyclopentane-1-carbonitrile 175463-32-8, 1-tert-Butoxycarbonyl-4-oxopyrrolidine-3-carbonitrile 858668-96-9, 2-Aminocyclobutane-1-carbonitrile 858668-98-1, 3-(2-Phenyl-1H-imidazol-4-yl)propanoyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

IT 99280-85-0P, 1-Benzyl-4-formyl-2-phenylimidazole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazole, fused pyrazole, and imidazole derivs. as preventive and/or therapeutic agents for disease mediated by mitochondrial benzodiazepine receptor)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 5 ANSWERS ZCAPLUS COPYRIGHT 2009 ACS on STN
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
TI Preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compounds as therapeutic cannabinoid receptor ligands
ST nitrogen contg heterocycle prepn therapeutic cannabinoid receptor ligand; pain treatment nitrogen contg heterocycle cannabinoid receptor ligand
IT Immune disease
(cancer of immune system; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)
IT Pain
(inflammatory pain; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)

IT Pain
(neuropathic pain; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)
IT Analgesics
Anti-inflammatory agents
Antidiabetic agents
Antiobesity agents
Antitumor agents
Cardiovascular agents
Cardiovascular disease
Diabetes mellitus
Drug delivery systems
Human
Immune disease
Immunomodulators
Inflammation
Nervous system, disease
Nervous system agents
Neuroprotective agents
Obesity
Pain
Prophylaxis
Respiratory system agents
Respiratory system disease
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)
IT Cannabinoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type CB2; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)
IT 371-62-0P, 2-Fluoroethanol 1140917-43-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)
IT 1140917-13-0P 1140917-16-3P 1140917-18-5P 1140917-19-6P
1140917-20-9P 1140917-22-1P 1140917-24-3P 1140917-27-6P
1140917-29-8P 1140917-32-3P 1140917-34-5P 1140917-37-8P
1140917-41-4P 1140917-48-1P 1140917-49-2P 1140917-53-8P
1140917-54-9P 1140917-55-0P 1140917-56-1P 1140917-57-2P
1140917-58-3P 1140917-59-4P 1140917-60-7P 1140917-61-8P
1140917-62-9P 1140917-63-0P 1140917-64-1P 1140917-65-2P
1140917-66-3P 1140917-67-4P 1140917-68-5P 1140917-71-0P
1140917-75-4P 1140917-76-5P 1140917-77-6P 1140917-78-7P
1140917-79-8P 1140917-88-9P 1140917-89-0P 1140917-90-3P
1140917-91-4P 1140917-92-5P 1140917-94-7P 1140917-95-8P
1140918-00-8P 1140918-01-9P 1140918-02-0P 1140918-03-1P
1140918-04-2P 1140918-05-3P 1140918-06-4P 1140918-07-5P
1140918-08-6P 1140918-09-7P 1140918-10-0P 1140918-11-1P
1140918-12-2P 1140918-14-4P 1140918-15-5P 1140918-16-6P
1140918-18-8P 1140918-19-9P 1140918-24-6P 1140918-30-4P
1140918-36-0P 1140918-40-6P 1140918-41-7P 1140918-42-8P
1140918-43-9P 1140918-44-0P 1140918-45-1P 1140918-46-2P
1140918-47-3P 1140918-48-4P 1140918-49-5P 1140918-50-8P
1140918-51-9P 1140918-52-0P 1140918-54-2P 1140918-57-5P
1140918-59-7P 1140918-60-0P 1140918-61-1P 1140918-66-6P
1140918-67-7P 1140918-68-8P 1140918-69-9P 1140918-70-2P
1140918-71-3P 1140918-72-4P 1140918-73-5P 1140918-74-6P

1140918-75-7P 1140918-78-0P 1140918-79-1P 1140918-82-6P
1140918-83-7P 1140918-84-8P 1140918-85-9P 1141889-94-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)

IT 401892-81-7P, 3-(Pentafluorosulfanyl)benzoyl chloride 1140917-17-4P, 5-Cyclopropyl-3-[(tetrahydrofuran-2-yl)methyl]-1,3,4-thiadiazol-2(3H)-imine 1140917-33-4P, 5-Methyl-1-[(tetrahydrofuran-2-yl)methyl]pyridin-2(1H)-imine hydrobromide 1140917-39-0P 1140917-47-0P, 2-Ethoxy-5-(trifluoromethyl)benzoyl chloride
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)

IT 57-57-8, 2-Oxetanone 75-64-9, 2-Methylpropan-2-amine, reactions 75-89-8, 2,2,2-Trifluoroethanol 76-83-5 79-19-6, Thiosemicarbazide 98-59-9, 4-Methylbenzene-1-sulfonyl chloride 104-75-6, 2-Ethylhexan-1-amine 108-01-0, 2-(Dimethylamino)ethanol 109-85-3, 2-Methoxyethanamine 110-18-9, N,N,N',N'-Tetramethylethane-1,2-diamine 110-52-1, 1,4-Dibromobutane 110-80-5, 2-Ethoxyethanol 111-35-3, 3-Ethoxypropan-1-ol 124-68-5, 2-Amino-2-methylpropan-1-ol 134-11-2, 2-Ethoxybenzoic acid 359-13-7, 2,2-Difluoroethanol 406-34-8, 2-Fluoroethanamine 407-25-0, 2,2,2-Trifluoroacetic anhydride 430-50-2, 1-Fluoropropan-2-ol 533-67-5, (3S,4R)-3,4,5-Trihydroxypentanal 556-82-1, 3-Methylbut-2-en-1-ol 598-74-3, 3-Methylbutan-2-amine 616-24-0, 3-Pentanamine 657-05-6, 2-Chloro-5-(trifluoromethyl)benzoyl chloride 833-96-5, 3-(Pentafluorothio)benzoic acid 1120-56-5, Methylenecyclobutane 1192-30-9, 2-(Bromomethyl)tetrahydrofuran 1589-49-7, 3-Methoxypropan-1-ol 1603-41-4, 5-Methylpyridin-2-amine 2026-48-4, (S)-2-Amino-3-methylbutan-1-ol 2217-40-5, 1,2,3,4-Tetrahydronaphthalen-1-amine 2568-33-4, 3-Methylbutane-1,3-diol 2941-29-9, 2-Oxocyclopentanecarbonitrile 3433-90-7, 2-Methoxy-5-cyanobenzoyl chloride 3438-16-2, 5-Chloro-2-methoxybenzoic acid 3824-87-1, 2-Fluoropropan-1-ol 4088-84-0, 2-Fluoro-5-(trifluoromethyl)benzonitrile 4637-24-5 4864-01-1, 2-Methoxy-5-(trifluoromethyl)benzoic acid 5241-58-7, (S)-2-Amino-3-phenylpropanamide 5452-35-7, Cycloheptanamine 5469-26-1, 1-Bromo-3,3-dimethylbutan-2-one 5813-64-9, 2,2-Dimethylpropan-1-amine 6206-25-3 6321-23-9, 4-Methylcyclohexanamine 6914-76-7, 1-Methylcyclopropane-1-carboxylic acid 7202-43-9, (R)-(Tetrahydrofuran-2-yl)methylamine 7533-40-6, (S)-2-Amino-4-methylpentan-1-ol 7547-97-9 14445-54-6, (2S,3S)-2-Amino-3-methylpentanamide 15833-61-1, (Tetrahydrofuran-3-yl)methanol 16466-61-8 17342-08-4, (S)-5-(Hydroxymethyl)pyrrolidin-2-one 17397-24-9, (S)-Hex-5-en-2-ol 17397-29-4, (R)-Hex-5-en-2-ol 17430-98-7, (S)-1-Cyclohexylethanamine 17768-41-1, (Adamantylmethyl)amine 17869-77-1, Trimethyl(2-methyl-3-butyn-2-yloxy)silane 18162-48-6, tert-Butyldimethylsilyl chloride 21900-51-6, 2-Chloro-5-fluorobenzoyl chloride 22374-89-6, 4-Phenylbutan-2-amine 22415-59-4, ((R)-Tetrahydrofuran-2-yl)methanol 25015-63-8, 4,4,5,5-Tetramethyl-1,3,2-dioxaborolane 33252-26-5, 4-tert-Butylpyridin-2-amine 34723-82-5, 2-(Bromomethyl)tetrahydro-2H-pyran 39222-73-6, 2-Amino-5-tert-butyl-1,3,4-thiadiazole 40615-36-9 55809-36-4, 5-tert-Butylisoxazol-3-amine 56539-66-3, 3-Methoxy-3-methylbutan-1-ol 56663-76-4, 2,2-Dimethyl-3-butynoic acid 57203-01-7 57235-50-4, 5-Cyclopropyl-1,3,4-thiadiazol-2-amine 59997-51-2,

4,4-Dimethyl-3-oxopentanenitrile 62910-63-8, 2-Methoxy-5-bromobenzoyl chloride 64507-07-9, 2-Methoxy-5-(trifluoromethyl)benzoyl chloride 66673-40-3, (R)-5-(Hydroxymethyl)pyrrolidin-2-one 73522-42-6, ((1S,2R,5S)-6,6-Dimethylbicyclo[3.1.1]heptan-2-yl)methanamine 82560-12-1, 3-tert-Butyl-2H-pyrazol-5-amine 83306-84-7, (R)-Tetrahydrofuran-2-ol 89226-12-0, (S)-2-Amino-N-methyl-3,3-dimethylbutanamide 104641-59-0, (S)-1-Methylpyrrolidin-3-ol 107496-54-8, 3,3-Difluorocyclobutanecarboxylic acid 108551-60-6, 5-Bromo-2,3-dihydrobenzofuran-7-carbonyl chloride 111857-74-0, (S)-Tetrahydrofuran-2-ol 112245-13-3, (S)-2-Amino-3,3-dimethylbutan-1-ol 115029-23-7, 2-Fluoro-5-(trifluoromethyl)benzoic acid 116422-39-0, (S)-2-Methoxypropan-1-ol 141699-55-0, tert-Butyl 3-hydroxyazetidine-1-carboxylate 154669-49-5, 4-Methylbenzenesulfonic acid (S)-(2-oxo-1,3-oxazolidin-4-yl)methyl ester 165059-42-7, (E)-2-(3-Methoxyprop-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 171243-30-4, 3-Fluoro-5-trifluoromethylbenzoyl chloride 172324-68-4 183616-18-4, 3-(Hydroxymethyl)cyclobutanone 207981-46-2, 2-Fluoro-5-(trifluoromethyl)benzoyl chloride 208173-19-7, 2-Fluoro-3-(trifluoromethyl)benzoyl chloride 240800-48-0, 2,3,5-Trifluorobenzoyl chloride 261763-03-5, 3-Chloro-2-fluoro-5-(trifluoromethyl)benzoyl chloride 261952-08-3, 2-Methyl-5-(trifluoromethyl)benzoyl chloride 277756-45-3, 1-(Trifluoromethyl)cyclobutanecarboxylic acid 277756-46-4, 1-(Trifluoromethyl)cyclopropanecarboxylic acid 472809-65-7, 2-Ethoxy-5-(trifluoromethyl)benzoic acid 773140-42-4 876747-18-1, (R)-2-Fluoropropan-1-ol 889940-13-0, 3,3,3-Trifluoro-2,2-dimethylpropanoic acid 895157-70-7, 2,2,3,3-Tetrafluoro-1-methylcyclobutanecarbonyl chloride 944836-48-0, 2-Bromo-5-trifluoromethylbenzoyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic
compds. as therapeutic cannabinoid receptor ligands)

IT 6970-72-5P, 1-(Hydroxymethyl)cyclobutanol 13942-76-2P, (2R,3S)-Pentane-1,2,3,5-tetraol 15833-63-3P, (Tetrahydrofuran-3-yl)methyl 4-methylbenzenesulfonate 22415-60-7P, 4-Methylbenzenesulfonic acid (2R)-tetrahydrofuran-2-ylmethyl ester 29568-33-0P, 5-Chloro-2-methoxybenzoyl chloride 73089-93-7P, 1-(2-Hydroxyethyl)cyclopentanol 88485-78-3P, 3-(1-Methylcyclopropyl)-3-oxopropanenitrile 91547-59-0P, (2R,3S)-2-(Hydroxymethyl)tetrahydrofuran-3-ol 95049-01-7P, (2R,3S)-2-[[Bis(4-methoxyphenyl)(phenyl)methoxy]methyl]tetrahydrofuran-3-ol 97987-64-9P, 5-(1,1-Dimethylprop-2-ynyl)-1,3,4-thiadiazol-2-amine 114114-90-8P, 4-Methylbenzenesulfonic acid (2S)-tetrahydrofuran-2-ylmethyl ester 432509-85-8P, N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-5-chloro-2-methoxybenzamide 681128-39-2P 908269-41-0P, 5-(1-Methylcyclopropyl)-1,3,4-thiadiazol-2-amine 959600-77-2P, [[(cis-3-Methoxycyclobutyl)methoxy]methyl]benzene 959600-78-3P, (cis-3-Methoxycyclobutyl)methanol 959749-92-9P, [[cis-3-[(Benzyloxy)methyl]cyclobutyl]oxy](tert-butyl)dimethylsilane 959749-93-0P, [cis-3-[(tert-Butyldimethylsilyl)oxy]cyclobutyl]methanol 1032464-60-0P, 5-[1-(Trifluoromethyl)cyclobutyl]-1,3,4-thiadiazol-2-amine 1034356-15-4P, (R)-Tetrahydrofuran-2-ylmethylcyanamide 1138162-60-3P 1140917-14-1P, 5-[1-(Trifluoromethyl)cyclopropyl]-1,3,4-thiadiazol-2-amine 1140917-15-2P 1140917-21-0P, 5-Chloro-2-methoxy-N-[5-(1-methylcyclopropyl)-1,3,4-thiadiazol-2-yl]benzamide 1140917-23-2P, 5-Chloro-N-[5-(1,1-dimethylprop-2-ynyl)-1,3,4-thiadiazol-2-yl]-2-methoxybenzamide 1140917-25-4P, 5-(2,2,3,3-Tetrafluoro-1-methylcyclobutyl)-1,3,4-thiadiazol-2-amine 1140917-26-5P, 5-Chloro-2-methoxy-N-[5-(2,2,3,3-tetrafluoro-1-methylcyclobutyl)-1,3,4-thiadiazol-2-yl]benzamide 1140917-28-7P 1140917-30-1P,

5-(2,2,2-Trifluoro-1,1-dimethylethyl)-1,3,4-thiadiazol-2-amine
1140917-31-2P 1140917-36-7P 1140917-38-9P 1140917-40-3P
1140917-42-5P, (R)-5-tert-Butyl-3-[(tetrahydrofuran-2-yl)methyl]oxazol-
2(3H)-imine 1140917-44-7P, (R)-N-[3-tert-Butyl-1-[(tetrahydrofuran-2-
yl)methyl]-1H-pyrazol-5-yl]-2,2,2-trifluoroethanamide 1140917-45-8P
1140917-46-9P 1140917-50-5P 1140917-51-6P 1140917-52-7P
1140917-69-6P, (S)-2-[(Tetrahydrofuran-2-yl)methyl]-2,4,5,6-
tetrahydrocyclopenta[c]pyrazol-3-amine 1140917-70-9P
1140917-72-1P, (R)-3-(1-Methylcyclopropyl)-1-[(tetrahydrofuran-2-
yl)methyl]-1H-pyrazol-5-amine 1140917-73-2P 1140917-81-2P
1140917-82-3P 1140917-83-4P 1140917-84-5P 1140917-85-6P
1140917-87-8P 1140917-93-6P 1140917-96-9P,
(R)-[(Tetrahydrofuran-2-yl)methyl]hydrazine dihydrochloride
1140917-97-0P 1140917-98-1P, (R)-3-tert-Butyl-1-[(tetrahydrofuran-2-
yl)methyl]-1H-pyrazol-5-amine hydrochloride 1140917-99-2P
1140918-13-3P 1140918-17-7P, (R)-4-tert-Butyl-1-[(tetrahydrofuran-2-
yl)methyl]pyridin-2(1H)-imine 1140918-20-2P 1140918-21-3P
1140918-22-4P, 3-tert-Butyl-1-[(tetrahydro-2H-pyran-2-yl)methyl]-1H-
pyrazol-5-amine 1140918-23-5P, N-[3-tert-Butyl-1-[(tetrahydro-2H-pyran-2-
yl)methyl]-1H-pyrazol-5-yl]-2-methoxy-5-(trifluoromethyl)benzamide
1140918-25-7P 1140918-26-8P 1140918-27-9P 1140918-28-0P
1140918-29-1P 1140918-31-5P 1140918-32-6P 1140918-33-7P
1140918-34-8P 1140918-35-9P 1140918-37-1P, tert-Butyl
(5-tert-butyl-1,3,4-thiadiazol-2-yl)carbamate 1140918-38-2P
1140918-39-3P, (R)-5-tert-Butyl-3-[(tetrahydrofuran-2-yl)methyl]-1,3,4-
thiadiazol-2(3H)-imine 1140918-62-2P 1140918-63-3P,
3-tert-Butyl-1-[(tetrahydrofuran-3-yl)methyl]-N-trityl-1H-pyrazol-5-amine
1140918-64-4P, 3-tert-Butyl-1-[(tetrahydrofuran-3-yl)methyl]-1H-pyrazol-5-
amine 1140918-65-5P, N-[3-tert-Butyl-1-[(tetrahydrofuran-3-yl)methyl]-1H-
pyrazol-5-yl]-2-methoxy-5-(trifluoromethyl)benzamide 1140918-76-8P
1140918-77-9P 1140918-80-4P, (S)-2-[(1-Methylpyrrolidin-3-yl)oxy]-5-
(trifluoromethyl)benzonitrile 1140918-81-5P,
(S)-2-[(1-Methylpyrrolidin-3-yl)oxy]-5-(trifluoromethyl)benzoic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of pyrazoles, oxazoles, and other nitrogen-containing
heterocyclic
compds. as therapeutic cannabinoid receptor ligands)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 5 ANSWERS ZCAPLUS COPYRIGHT 2009 ACS on STN
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
TI Reactions of isatoic anhydride with some aminoheterocycles
ST isatoic anhydride heterocyclic amine amidation; heterocycle substituted
anthranilic acid amide prepn; anthranilamide heterocycle substituted deriv
prepn; tetrahydroquinazolinyl quinazolinone deriv prepn
IT Amides, preparation
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(aryl, heterocyclic; preparation of heterocycle-substituted anthranilic acid
amides via amidation reactions of isatoic anhydride with
aminoheterocycles)
IT Amines, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(heterocyclic; preparation of heterocycle-substituted anthranilic acid
amides via amidation reactions of isatoic anhydride with
aminoheterocycles)
IT Amidation
(preparation of heterocycle-substituted anthranilic acid amides via
amidation reactions of isatoic anhydride with aminoheterocycles)
IT 118-48-9, Isatoic anhydride 4149-06-8 4815-30-9 5805-39-0,

2-(2-Aminophenyl)benzimidazole 21599-37-1 24764-63-4 26093-31-2,
7-Amino-4-methylcoumarin 1001049-60-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocycle-substituted anthranilic acid amides via amidation reactions of isatoic anhydride with aminoheterocycles)
IT 1016638-23-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocycle-substituted anthranilic acid amides via amidation reactions of isatoic anhydride with aminoheterocycles)
IT 96057-32-8P 1016638-24-6P 1016638-25-7P 1016638-26-8P
1016638-27-9P 1016638-28-0P 1016638-29-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of heterocycle-substituted anthranilic acid amides via amidation reactions of isatoic anhydride with aminoheterocycles)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 5 ANSWERS ZCAPLUS COPYRIGHT 2009 ACS on STN
INCL 514336000; 548136000; 546283400; 548240000; 548365700; 548215000; 514374000; 514378000; 514406000; 514363000
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1
TI Preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compounds as therapeutic cannabinoid receptor ligands
ST nitrogen contg heterocycle prepn therapeutic cannabinoid receptor ligand; pain treatment nitrogen contg heterocycle cannabinoid receptor ligand
IT Immune disease
(cancer of immune system; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)
IT Pain
(inflammatory pain; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)
IT Pain
(neuropathic pain; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)
IT Analgesics
Anti-inflammatory agents
Antidiabetic agents
Antiobesity agents
Antitumor agents
Cardiovascular agents
Cardiovascular disease
Diabetes mellitus
Drug delivery systems
Human
Immune disease
Immunomodulators
Inflammation
Nervous system, disease
Nervous system agents
Neuroprotective agents
Obesity
Pain
Prophylaxis
Respiratory system agents
Respiratory system disease
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic

compds. as therapeutic cannabinoid receptor ligands)

IT Cannabinoid receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type CB2; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)

IT 371-62-0P, 2-Fluoroethanol 1140917-43-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)

IT 1140917-13-0P 1140917-16-3P 1140917-18-5P 1140917-19-6P
1140917-20-9P 1140917-22-1P 1140917-24-3P 1140917-27-6P
1140917-29-8P 1140917-32-3P 1140917-34-5P 1140917-37-8P
1140917-41-4P 1140917-48-1P 1140917-49-2P 1140917-53-8P
1140917-54-9P 1140917-55-0P 1140917-56-1P 1140917-57-2P
1140917-58-3P 1140917-59-4P 1140917-60-7P 1140917-61-8P
1140917-62-9P 1140917-63-0P 1140917-64-1P 1140917-65-2P
1140917-66-3P 1140917-67-4P 1140917-68-5P 1140917-71-0P
1140917-75-4P 1140917-76-5P 1140917-77-6P 1140917-78-7P
1140917-79-8P 1140917-88-9P 1140917-89-0P 1140917-90-3P
1140917-91-4P 1140917-92-5P 1140917-94-7P 1140917-95-8P
1140918-00-8P 1140918-01-9P 1140918-02-0P 1140918-03-1P
1140918-04-2P 1140918-05-3P 1140918-06-4P 1140918-07-5P
1140918-08-6P 1140918-09-7P 1140918-10-0P 1140918-11-1P
1140918-12-2P 1140918-14-4P 1140918-15-5P 1140918-16-6P
1140918-18-8P 1140918-19-9P 1140918-24-6P 1140918-30-4P
1140918-36-0P 1140918-40-6P 1140918-41-7P 1140918-42-8P
1140918-43-9P 1140918-44-0P 1140918-45-1P 1140918-46-2P
1140918-47-3P 1140918-48-4P 1140918-49-5P 1140918-50-8P
1140918-51-9P 1140918-52-0P 1140918-54-2P 1140918-57-5P
1140918-59-7P 1140918-60-0P 1140918-61-1P 1140918-66-6P
1140918-67-7P 1140918-68-8P 1140918-69-9P 1140918-70-2P
1140918-71-3P 1140918-72-4P 1140918-73-5P 1140918-74-6P
1140918-75-7P 1140918-78-0P 1140918-79-1P 1140918-82-6P
1140918-83-7P 1140918-84-8P 1140918-85-9P 1141889-94-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic compds. as therapeutic cannabinoid receptor ligands)

IT 401892-81-7P, 3-(Pentafluorosulfanyl)benzoyl chloride 1140917-17-4P
1140917-33-4P 1140917-39-0P 1140917-47-0P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic
compds. as therapeutic cannabinoid receptor ligands)

IT 57-57-8, 2-Oxetanone 75-64-9, 2-Methylpropan-2-amine, reactions
75-89-8, 2,2,2-Trifluoroethanol 76-83-5 79-19-6, Thiosemicarbazide
98-59-9, 4-Methylbenzene-1-sulfonyl chloride 104-75-6,
2-Ethylhexan-1-amine 108-01-0, 2-(Dimethylamino)ethanol 109-85-3,
2-Methoxyethanamine 110-18-9, N,N,N',N'-Tetramethylethane-1,2-diamine
110-52-1, 1,4-Dibromobutane 110-80-5, 2-Ethoxyethanol 111-35-3,
3-Ethoxypropan-1-ol 124-68-5, 2-Amino-2-methylpropan-1-ol 134-11-2,
2-Ethoxybenzoic acid 359-13-7, 2,2-Difluoroethanol 406-34-8,
2-Fluoroethanamine 407-25-0, 2,2,2-Trifluoroacetic anhydride 430-50-2,
1-Fluoropropan-2-ol 533-67-5, (3S,4R)-3,4,5-Trihydroxypentanal
556-82-1, 3-Methylbut-2-en-1-ol 598-74-3, 3-Methylbutan-2-amine
616-24-0, 3-Pentanamine 657-05-6, 2-Chloro-5-(trifluoromethyl)benzoyl

chloride 833-96-5, 3-(Pentafluorothio)benzoic acid 1120-56-5, Methylenecyclobutane 1192-30-9, 2-(Bromomethyl)tetrahydrofuran 1589-49-7, 3-Methoxypropan-1-ol 1603-41-4, 5-Methylpyridin-2-amine 2026-48-4, (S)-2-Amino-3-methylbutan-1-ol 2217-40-5, 1,2,3,4-Tetrahydronaphthalen-1-amine 2568-33-4, 3-Methylbutane-1,3-diol 2941-29-9, 2-Oxocyclopentanecarbonitrile 3433-90-7, 2-Methoxy-5-cyanobenzoyl chloride 3438-16-2, 5-Chloro-2-methoxybenzoic acid 3824-87-1, 2-Fluoropropan-1-ol 4088-84-0, 2-Fluoro-5-(trifluoromethyl)benzonitrile 4637-24-5 4864-01-1, 2-Methoxy-5-(trifluoromethyl)benzoic acid 5241-58-7, (S)-2-Amino-3-phenylpropanamide 5452-35-7, Cycloheptanamine 5469-26-1, 1-Bromo-3,3-dimethylbutan-2-one 5813-64-9, 2,2-Dimethylpropan-1-amine 6206-25-3 6321-23-9, 4-Methylcyclohexanamine 6914-76-7, 1-Methylcyclopropane-1-carboxylic acid 7202-43-9, (R)-(Tetrahydrofuran-2-yl)methylamine 7533-40-6, (S)-2-Amino-4-methylpentan-1-ol 7547-97-9 14445-54-6, (2S,3S)-2-Amino-3-methylpentanamide 15833-61-1, (Tetrahydrofuran-3-yl)methanol 16466-61-8 17342-08-4, (S)-5-(Hydroxymethyl)pyrrolidin-2-one 17397-24-9, (S)-Hex-5-en-2-ol 17397-29-4, (R)-Hex-5-en-2-ol 17430-98-7, (S)-1-Cyclohexylethanamine 17768-41-1, (Adamantylmethyl)amine 17869-77-1, Trimethyl(2-methyl-3-butyn-2-yloxy)silane 18162-48-6, tert-Butyldimethylsilyl chloride 21900-51-6, 2-Chloro-5-fluorobenzoyl chloride 22374-89-6, 4-Phenylbutan-2-amine 22415-59-4, ((R)-Tetrahydrofuran-2-yl)methanol 25015-63-8, 4,4,5,5-Tetramethyl-1,3,2-dioxaborolane 33252-26-5, 4-tert-Butylpyridin-2-amine 34723-82-5, 2-(Bromomethyl)tetrahydro-2H-pyran 39222-73-6, 2-Amino-5-tert-butyl-1,3,4-thiadiazole 40615-36-9 55809-36-4, 5-tert-Butylisoxazol-3-amine 56539-66-3, 3-Methoxy-3-methylbutan-1-ol 56663-76-4, 2,2-Dimethyl-3-butynoic acid 57203-01-7 57235-50-4, 5-Cyclopropyl-1,3,4-thiadiazol-2-amine 59997-51-2, 4,4-Dimethyl-3-oxopentanenitrile 62910-63-8, 2-Methoxy-5-bromobenzoyl chloride 64507-07-9, 2-Methoxy-5-(trifluoromethyl)benzoyl chloride 66673-40-3, (R)-5-(Hydroxymethyl)pyrrolidin-2-one 73522-42-6, ((1S,2R,5S)-6,6-Dimethylbicyclo[3.1.1]heptan-2-yl)methanamine 82560-12-1, 3-tert-Butyl-2H-pyrazol-5-amine 83306-84-7, (R)-Tetrahydrofuran-2-ol 89226-12-0, (S)-2-Amino-N-methyl-3,3-dimethylbutanamide 104641-59-0, (S)-1-Methylpyrrolidin-3-ol 107496-54-8, 3,3-Difluorocyclobutanecarboxylic acid 108551-60-6, 5-Bromo-2,3-dihydrobenzofuran-7-carbonyl chloride 111857-74-0, (S)-Tetrahydrofuran-2-ol 112245-13-3, (S)-2-Amino-3,3-dimethylbutan-1-ol 115029-23-7, 2-Fluoro-5-(trifluoromethyl)benzoic acid 116422-39-0, (S)-2-Methoxypropan-1-ol 141699-55-0, tert-Butyl 3-hydroxyazetidine-1-carboxylate 154669-49-5, 4-Methylbenzenesulfonic acid (S)-(2-oxo-1,3-oxazolidin-4-yl)methyl ester 165059-42-7, (E)-2-(3-Methoxyprop-1-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 171243-30-4, 3-Fluoro-5-trifluoromethylbenzoyl chloride 172324-68-4 183616-18-4, 3-(Hydroxymethyl)cyclobutanone 207981-46-2, 2-Fluoro-5-(trifluoromethyl)benzoyl chloride 208173-19-7, 2-Fluoro-3-(trifluoromethyl)benzoyl chloride 240800-48-0, 2,3,5-Trifluorobenzoyl chloride 261763-03-5, 3-Chloro-2-fluoro-5-(trifluoromethyl)benzoyl chloride 261952-08-3, 2-Methyl-5-(trifluoromethyl)benzoyl chloride 277756-45-3, 1-(Trifluoromethyl)cyclobutanecarboxylic acid 277756-46-4, 1-(Trifluoromethyl)cyclopropanecarboxylic acid 472809-65-7, 2-Ethoxy-5-(trifluoromethyl)benzoic acid 773140-42-4 876747-18-1, (R)-2-Fluoropropan-1-ol 889940-13-0, 3,3,3-Trifluoro-2,2-dimethylpropanoic acid 895157-70-7, 2,2,3,3-Tetrafluoro-1-methylcyclobutanecarbonyl chloride 944836-48-0, 2-Bromo-5-trifluoromethylbenzoyl chloride

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic
compds. as therapeutic cannabinoid receptor ligands)

IT 6970-72-5P, 1-(Hydroxymethyl)cyclobutanol 13942-76-2P, (2R,3S)-Pentane-1,2,3,5-tetraol 15833-63-3P, (Tetrahydrofuran-3-yl)methyl 4-methylbenzenesulfonate 22415-60-7P, 4-Methylbenzenesulfonic acid (2R)-tetrahydrofuran-2-ylmethyl ester 29568-33-0P, 5-Chloro-2-methoxybenzoyl chloride 73089-93-7P, 1-(2-Hydroxyethyl)cyclopentanol 88485-78-3P, 3-(1-Methylcyclopropyl)-3-oxopropanenitrile 91547-59-0P, (2R,3S)-2-(Hydroxymethyl)tetrahydrofuran-3-ol 95049-01-7P, (2R,3S)-2-[[Bis(4-methoxyphenyl)(phenyl)methoxy]methyl]tetrahydrofuran-3-ol 97987-64-9P, 5-(1,1-Dimethylprop-2-ynyl)-1,3,4-thiadiazol-2-amine 114114-90-8P, 4-Methylbenzenesulfonic acid (2S)-tetrahydrofuran-2-ylmethyl ester 432509-85-8P, N-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-5-chloro-2-methoxybenzamide 681128-39-2P 908269-41-0P, 5-(1-Methylcyclopropyl)-1,3,4-thiadiazol-2-amine 959600-77-2P, [[(cis-3-Methoxycyclobutyl)methoxy]methyl]benzene 959600-78-3P, (cis-3-Methoxycyclobutyl)methanol 959749-92-9P, [[cis-3-[(Benzyloxy)methyl]cyclobutyl]oxy](tert-butyl)dimethylsilane 959749-93-0P, [cis-3-[(tert-Butyldimethylsilyl)oxy]cyclobutyl]methanol 1032464-60-0P, 5-[1-(Trifluoromethyl)cyclobutyl]-1,3,4-thiadiazol-2-amine 1034356-15-4P, (R)-Tetrahydrofuran-2-ylmethylcyanamide 1138162-60-3P 1140917-14-1P 1140917-15-2P 1140917-21-0P 1140917-23-2P 1140917-25-4P 1140917-26-5P 1140917-28-7P 1140917-30-1P 1140917-31-2P 1140917-36-7P 1140917-38-9P 1140917-40-3P 1140917-42-5P 1140917-44-7P 1140917-45-8P 1140917-46-9P 1140917-50-5P 1140917-51-6P 1140917-52-7P 1140917-69-6P 1140917-70-9P 1140917-72-1P 1140917-73-2P 1140917-81-2P 1140917-82-3P 1140917-83-4P 1140917-84-5P 1140917-85-6P 1140917-87-8P 1140917-93-6P 1140917-96-9P 1140917-97-0P 1140917-98-1P 1140917-99-2P 1140918-13-3P 1140918-17-7P 1140918-20-2P 1140918-21-3P 1140918-22-4P 1140918-23-5P 1140918-25-7P 1140918-26-8P 1140918-27-9P 1140918-28-0P 1140918-29-1P 1140918-31-5P 1140918-32-6P 1140918-33-7P 1140918-34-8P 1140918-35-9P 1140918-37-1P 1140918-38-2P 1140918-39-3P 1140918-62-2P 1140918-63-3P 1140918-64-4P 1140918-65-5P 1140918-76-8P 1140918-77-9P 1140918-80-4P 1140918-81-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazoles, oxazoles, and other nitrogen-containing heterocyclic
compds. as therapeutic cannabinoid receptor ligands)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 5 ANSWERS ZCAPLUS COPYRIGHT 2009 ACS on STN
CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
TI Preparation of phenylpyrazole derivatives as P2X7 receptor antagonists
ST pyrazole cyclopentapyrazole thienopyrazole phenyl prepn P2X7 Purinoceptor antagonist
IT Nervous system, disease
(Huntington's chorea; preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)
IT Purinoceptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(P2x7, antagonists of; preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)
IT Pain

(inflammatory pain, chronic; preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)

IT Pain
(neuropathic pain; preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)

IT Alzheimer's disease
Amyotrophic lateral sclerosis
Analgesics
Anti-Alzheimer's agents
Anti-inflammatory agents
Antidepressants
Antiparkinsonian agents
Antirheumatic agents
Central nervous system, disease
Depression
Human
Inflammation
Lewy body dementia
Multiple sclerosis
Neurodegenerative disease
Pain
Parkinson's disease
Rheumatoid arthritis
(preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)

IT Brain disease
(trauma; preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)

IT 936840-72-1P, N-[2-(2,3-Dichlorophenyl)-2H-pyrazol-3-yl]-2-methylbenzamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)

IT 936840-74-3P, [2-(2,3-Dichlorophenyl)-2H-pyrazol-3-yl](2-methylbenzyl)amine 936840-75-4P, [2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl][(pyridin-3-yl)methyl]amine 936840-78-7P, [2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl](2-methylbenzyl)amine 936840-79-8P, [2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl][(2-methylpyridin-3-yl)methyl]amine 936840-81-2P, [2-(2,3-Dichlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl][(2-methylpyridin-3-yl)methyl]amine 936840-84-5P, 5-Benzylamino-1-(2,3-dichlorophenyl)-1H-pyrazole-4-carbonitrile 936840-86-7P, [2-(2,3-Dichlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl](2-methylbenzyl)amine 936840-88-9P, 1-(2,3-Dichlorophenyl)-5-[[(pyridin-3-yl)methyl]amino]-1H-pyrazole-4-carbonitrile 936840-89-0P, [2-(2,3-Dichlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl][(2-methylpyridin-3-yl)methyl]amine 936840-92-5P, 1-(2,3-Dichlorophenyl)-5-[[(2-methylpyridin-3-yl)methyl]amino]-1H-pyrazole-4-carbonitrile 936840-93-6P, [2-(2,3-Dichlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl][(2-phenoxypyridin-3-yl)methyl]amine 936840-95-8P, [2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl][(2-phenoxypyridin-3-yl)methyl]amine 936840-97-0P, [2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl](2-phenoxybenzyl)amine 936840-99-2P, [[2-(3-Chlorophenoxy)pyridin-3-yl]methyl][2-(2,3-dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)

IT 100-46-9, Benzylamine, reactions 123-06-8 933-88-0, 2-Methylbenzoyl

chloride 2243-42-7, 2-Phenoxybenzoic acid 2941-29-9,
2-Oxocyclopentanecarbonitrile 3222-56-8, 2-Methylnicotinic acid
3731-52-0, [(Pyridin-3-yl)methyl]amine 4513-77-3,
2-Oxocyclohexanecarbonitrile 10400-19-8, Nicotinoyl chloride
16563-14-7, 4-Oxotetrahydrothiophene-3-carbonitrile 21938-47-6,
(2,3-Dichlorophenyl)hydrazine hydrochloride 35620-71-4,
2-Phenoxynicotinic acid 54629-11-7 58539-64-3,
[(2-Methylpyridin-3-yl)methyl]amine
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)

IT 73594-95-3P, 5-Amino-1-(2,3-dichlorophenyl)-1H-pyrazole-4-carbonitrile
936840-73-2P, [2-(2,3-Dichlorophenyl)-2H-pyrazol-3-yl]amine
936840-76-5P, 2-(2,3-Dichlorophenyl)-2,4,5,6-
tetrahydrocyclopenta[c]pyrazol-3-amine 936840-77-6P,
N-[2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-
yl]nicotinamide 936840-80-1P,
N-[2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-2-
methylnicotinamide 936840-82-3P,
[2-(2,3-Dichlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]amine
936840-83-4P, N-[2-(2,3-Dichlorophenyl)-2,6-dihydro-4H-thieno[3,4-
c]pyrazol-3-yl]-2-methylnicotinamide 936840-85-6P,
5-Bromo-1-(2,3-dichlorophenyl)-1H-pyrazole-4-carbonitrile 936840-87-8P,
N-[2-(2,3-Dichlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-2-
methylbenzamide 936840-90-3P, [2-(2,3-Dichlorophenyl)-4,5,6,7-tetrahydro-
2H-indazol-3-yl]amine 936840-91-4P,
N-[2-(2,3-Dichlorophenyl)-4,5,6,7-tetrahydro-2H-indazol-3-yl]-2-
methylnicotinamide 936840-94-7P,
N-[2-(2,3-Dichlorophenyl)-2,6-dihydro-4H-thieno[3,4-c]pyrazol-3-yl]-2-
phenoxynicotinamide 936840-96-9P,
N-[2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-2-
phenoxynicotinamide 936840-98-1P,
N-[2-(2,3-Dichlorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl]-2-
phenoxybenzamide 936841-00-8P,
2-(3-Chlorophenoxy)-N-[2-(2,3-dichlorophenyl)-2,4,5,6-
tetrahydrocyclopenta[c]pyrazol-3-yl]nicotinamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of Ph pyrazoles and their analogs as P2X7 receptor antagonists)

ALL ANSWERS HAVE BEEN SCANNED

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.49	9.42

FILE 'REGISTRY' ENTERED AT 12:54:34 ON 15 JUN 2009

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JUN 2009 HIGHEST RN 1157585-76-6
DICTIONARY FILE UPDATES: 14 JUN 2009 HIGHEST RN 1157585-76-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

```
  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> analyze l4 1-280 LC
L8          ANALYZE L4 1-280 LC :       1 TERM

=> d
L8          ANALYZE L4 1-280 LC :       1 TERM

TERM #   # OCC  # DOC  % DOC LC
------ ------- ------ ------ ---------------
     1     280    280 100.00 CHEMCATS
*********  END OF L8 ***


=> file chemcats
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      16.52      25.94

FILE 'CHEMCATS' ENTERED AT 12:56:44 ON 15 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)


FILE LAST UPDATED 13 JUNE 2009 (20090613/UP)

For details on recent updates in CHEMCATS, enter NEWS FILE at an arrow
prompt.  For the list of suppliers currently in the file, enter
HELP SPA, HELP SPB, HELP SPC, HELP SPDH, HELP SPIL, HELP SPMN, HELP SPOQ,
HELP SPRS, and HELP SPTZ.  For the list of current catalogs, enter
HELP CTA, HELP CTB, HELP CTC, HELP CTDH, HELP CTIL, HELP CTMN, HELP
CTOQ, HELP CTRS, and HELP CTTZ.

This database is provided on an "as is" basis.  Please consult the
suppliers for current information regarding pricing, regional
availability, available quantities, purities, etc.  THERE ARE NO
WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED.  ACS is not
liable for any loss of profit, goodwill or any other damages arising
out of the use of this database.

CHEMCATS now contains more than 35 million records.  See HELP CONTENT
and NEWS FILE for details.

=> s l4
L9          827 L4

=> s l9 and pd<20041226
             0 PD<20041226
                 (PD<20041226)
L10          0 L9 AND PD<20041226

=> s l9 and pd>20041226
      35000716 PD>20041226
```

```
                (PD>20041226)
L11         827 L9 AND PD>20041226

=> s l9 and ed<20041226
      15067190 ED<20041226
                (ED<20041226)
L12           0 L9 AND ED<20041226

=> s l9 and ed>20041226
      52164699 ED>20041226
                (ED>20041226)
L13         827 L9 AND ED>20041226

=> analyze l9 1-827 pd
L14          ANALYZE L9 1-827 PD :        4 TERMS

=> d
L14          ANALYZE L9 1-827 PD :        4 TERMS

TERM #   # OCC  # DOC  % DOC PD
------ ------- ------ ------ ---------------
     1     279    279  33.74 20 FEB 2009
     2     270    270  32.65 9 FEB 2009
     3     262    262  31.68 8 JAN 2009
     4      16     16   1.93 1 JAN 2009
*********  END OF L14***


=> s l9 and 20090220/pd
       4607574 20090220/PD
                (20090220/PD)
L15         279 L9 AND 20090220/PD

=> s l9 and 20090209/pd
       7218445 20090209/PD
                (20090209/PD)
L16         270 L9 AND 20090209/PD

=> s l9 and 20090108/pd
       1273629 20090108/PD
                (20090108/PD)
L17         262 L9 AND 20090108/PD

=> s l9 and 20090101/pd
       1653588 20090101/PD
                (20090101/PD)
L18          16 L9 AND 20090101/PD

=> d l15 all 200
THE ESTIMATED COST FOR THIS REQUEST IS 4.29 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L15  ANSWER 200 OF 279  CHEMCATS COPYRIGHT 2009 ACS on STN
Accession No.       (AN): 2059840919  CHEMCATS
Catalog Name        (CO): Ambinter Stock Screening Collection
Publication Date    (PD): 20 Feb 2009
Order Number        (ON): PB203854944
Chemical Name       (CN): Chemical name not yet assigned
CAS Registry No.    (RN): 1043143-32-3
Supplementary Term  (ST): CHEMICAL LIBRARY
Structure               :
```



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

Ambinter
50, avenue de Versailles
Paris, F-75016
France

Phone: (33-1) 45 24 48 60
Fax: (33-1) 45 24 62 41
Email: contact@ambinter.com
Web: http://www.ambinter.com

=> d l16 all 170
THE ESTIMATED COST FOR THIS REQUEST IS 4.29 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L16 ANSWER 170 OF 270 CHEMCATS COPYRIGHT 2009 ACS on STN
Accession No. (AN): 2069388510 CHEMCATS
Catalog Name (CO): Aurora Screening Library
Publication Date (PD): 9 Feb 2009
Order Number (ON): kuk-1454874
Chemical Name (CN): Benzeneacetamide,
3-fluoro-N-(2,4,5,6-tetrahydro-2-phenyl-3-
cyclopentapyrazolyl)-
CAS Registry No. (RN): 1043105-34-5
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

Aurora Fine Chemicals LLC
7929 Silverton Ave.
Suite 609
San Diego, CA, 92126

USA

Phone: +1 858 549 4700
Fax: +1 858 549 4701
Email: aurora@aurorafinechemicals.com
Web: http://www.aurorafinechemicals.com

Aurora Fine Chemicals Ltd
Reininghausstrasse 49
Graz, A-8020
Austria

Email: aurora@aurorafinechemicals.com
Web: http://www.aurorafinechemicals.com

=> d l15 ide 200
THE ESTIMATED COST FOR THIS REQUEST IS 2.15 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L15 ANSWER 200 OF 279 CHEMCATS COPYRIGHT 2009 ACS on STN
Accession No. (AN): 2059840919 CHEMCATS
Catalog Name (CO): Ambinter Stock Screening Collection
Publication Date (PD): 20 Feb 2009
Order Number (ON): PB203854944
Chemical Name (CN): Chemical name not yet assigned
CAS Registry No. (RN): 1043143-32-3
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



=> d l17 ide 180
THE ESTIMATED COST FOR THIS REQUEST IS 2.15 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L17 ANSWER 180 OF 262 CHEMCATS COPYRIGHT 2009 ACS on STN
Accession No. (AN): 2051525169 CHEMCATS
Catalog Name (CO): UkrOrgSynthesis Screening Collection
Publication Date (PD): 8 Jan 2009
Order Number (ON): PB203849986
Chemical Name (CN): Chemical name not yet assigned
CAS Registry No. (RN): 1043104-73-9
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



=> d l18 all 5
THE ESTIMATED COST FOR THIS REQUEST IS 4.29 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L18 ANSWER 5 OF 16 CHEMCATS COPYRIGHT 2009 ACS on STN
Accession No. (AN): 2068127436 CHEMCATS
Catalog Name (CO): Enamine Screening Library
Publication Date (PD): 1 Jan 2009
Order Number (ON): T6186226
Chemical Name (CN): 4H-1,4-Benzoxazine-4-acetamide, 2,3-dihydro-2-methyl-3-oxo-N-(2,4,5,6-tetrahydro-2-phenyl-3-cyclopentapyrazolyl)-
CAS Registry No. (RN): 1090563-44-2
Supplementary Term (ST): CHEMICAL LIBRARY
Structure :



PRICES

Quantity : milligram quantities, Price: contact supplier

COMPANY INFORMATION

Enamine
23 Alexandra Matrosova Street
Kiev, 01103
Ukraine

Phone: +380 44 537 32 18
Fax: +380 44 537 32 53
Email: enamine@enamine.net
Web: http://www.enamine.net

=> d his

(FILE 'HOME' ENTERED AT 12:45:35 ON 15 JUN 2009)

FILE 'REGISTRY' ENTERED AT 12:46:05 ON 15 JUN 2009

```
                ACTIVATE S10584280/A
               ---------
L1              STR
L2          291 SEA FILE=REGISTRY SSS FUL L1
               ---------

     FILE 'REGISTRY' ENTERED AT 12:47:21 ON 15 JUN 2009
L3           16 S L2
L4          280 S L2 NOT CAPLUS/LC
L5           11 S L2 NOT L4

     FILE 'ZCAPLUS' ENTERED AT 12:50:28 ON 15 JUN 2009
L6            5 S L5
L7            5 S L2

     FILE 'REGISTRY' ENTERED AT 12:54:34 ON 15 JUN 2009
L8           ANALYZE L4 1-280 LC :       1 TERM

     FILE 'CHEMCATS' ENTERED AT 12:56:44 ON 15 JUN 2009
L9          827 S L4
L10           0 S L9 AND PD<20041226
L11         827 S L9 AND PD>20041226
L12           0 S L9 AND ED<20041226
L13         827 S L9 AND ED>20041226
L14         ANALYZE L9 1-827 PD :       4 TERMS
L15         279 S L9 AND 20090220/PD
L16         270 S L9 AND 20090209/PD
L17         262 S L9 AND 20090108/PD
L18          16 S L9 AND 20090101/PD

=> exit
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      74.52     100.46

STN INTERNATIONAL LOGOFF AT 13:23:53 ON 15 JUN 2009
```